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MIRNA EXPRESSION CHANGES IN ARSENIC-INDUCED SKIN CANCER IN 
VITRO AND IN VIVO 
Laila Al-Eryani 
August 03, 2017 
Arsenic is a naturally prevalent metalloid. Chronic arsenic ingestion 
through drinking water causes skin cancer. Arsenic-induced cancer mechanisms 
are not well defined. Epigenetic changes, including microRNA expression 
changes, might be playing a role. This dissertation investigates the impact of 
miRNA expression changes in arsenic-induced skin cancer. MiRNA expression 
was measure and compared using 3 different techniques, RTq-PCR, 
hybridization arrays and RNA-sequencing. MiRNAs differential expression in skin 
lesions was phenotype- and stage-related. Immortalized human keratinocytes 
(HaCaT) were transformed by chronic low arsenite exposure serving as a model 
for arsenic-induced skin carcinogenesis. Early changes in miRNAs and target 
mRNAs contribute to arsenic-induced carcinogenesis. Throughout the time 
course of arsenic exposure, dysregulation of cells’ growth and cancer-related 
pathways were identified. Comparisons between the miRNA profiles in lesions 
and cells predict some miRNAs may serve as biomarkers and/or therapeutic 
targets for arsenic-induced tumors. This dissertation provides strong evidences 
of epigenetic changes related to carcinogenesis in arsenic-induced skin cancer.
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Arsenic is a naturally occurring element that causes a variety of health 
complications including cancer. Arsenic-induced carcinogenesis mechanisms are 
still controversial. Several mechanisms including epigenetic changes are 
proposed. This work is focused on profiling the epigenetic changes, miRNAs 
changes in particular, in arsenic-induced skin cancers and premalignant lesions 
from humans chronically exposed to high levels of arsenic in drinking water and 
in an arsenic-induced skin cancer cell culture model. The results contribute to 
understanding the role of changes in expression of miRNAs and their target 
genes in the carcinogenesis process. The results also help evaluate the arsenic-
induced skin cancer cell culture model as a squamous cell carcinoma (SCC) 
model. 
Arsenic 
Arsenic is a toxic metalloid that is prevalent in the earth’s crust. Arsenic is 
an acknowledged carcinogen for over 20 years (1). In fact, the skin is the primary 
target organ for arsenic toxicity and Sir Jonathan Hutchinson was the first to 
report skin cancer in patients consuming arsenic-based medications in 1887/88 
(2). Arsenic has been known throughout history as a medicine and a poison. It 
has been used in many medical applications since ancient times in traditional 
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medicines. It was used to kill pests and humans and as a chemical warfare 
agent. 
Environmental arsenic contamination can be from natural sources or man-
made sources such as arsenic-based pesticides, wood preservatives, feed 
additives and industrial waste (3). Humans are mainly exposed to arsenic 
through ingestion and the main source is drinking water. Arsenic exists in 
multiple species in the environment. Aqueous inorganic oxyanions of arsenic, 
arsenite (As III) and arsenate (As V), are the predominant forms of arsenic in 
underground water (4). Other sources of arsenic ingestion are food (plants grown 
with arsenic contaminated water or on contaminated soil, seafood and meat of 
animals drinking arsenic contaminated water or receiving arsenical growth 
stimulants in their feed) (3, 4). Occupational exposures are common among 
farmers using arsenic-based pesticides and workers in factories producing these 
pesticides or where arsenic is used for industrial purposes such in as the glass 
industry, semiconductors and wood preservatives (e.g. copper–chromium–
arsenic (CCA) treated wood) (4).  
Arsenic in drinking water is a global health problem. There are large 
populations in parts of the world that are highly affected such as the Ganges 
delta encompassing Bangladesh and West Bengal, India, as well as areas in 
Taiwan, China, Nepal, Viet Nam, Argentina, Bolivia, Chile, Mexico and the U.S.A. 
(5). Arsenic has been linked to several health problems including pregnancy 
complications and teratogenicity, developmental defects, neurotoxicity, diabetes, 
pulmonary disease, cardiovascular disease, vascular disease, skin lesions and 
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cancers (6, 7). Arsenic causes several cancers including nonmelanoma skin, 
lung, bladder, kidney and liver cancers (8). Arsenic carcinogenesis mechanisms 
are not well understood and remain controversial. This dissertation is focused on 
understanding molecular changes contributing to skin cancer.  
Skin Cancer 
Skin cancer is the most prevalent form of all cancers (9). Most skin 
cancers are a consequence of mutations resulting from DNA damage caused by 
the ultraviolet radiation in sunlight (10). The second most frequent cause of skin 
cancer is chronic arsenic exposure. In populations exposed to high levels of 
arsenic in their drinking water and food, arsenic is a leading cause of skin cancer 
(11, 12). The skin is the primary target organ for arsenic toxicity. Arsenic-induced 
skin toxicity symptoms first appear as pigmentary changes including raindrop-
shaped lesions and diffuse dark brown lesions followed by arsenical keratosis in 
the palms, soles and trunk, followed by multiple cutaneous malignancies (13-16). 
Long-term ingestion of arsenic is associated with different types of skin cancer 
progressing from premalignant lesions, hyperkeratoses (HK), to the 
intraepidermal carcinoma (Bowen’s disease, BD), SCC, basal cell carcinoma 
(BCC), and Merkel cell carcinoma (13, 17). Sir Jonathan Hutchinson was the first 
to report skin cancer in patients consuming arsenic-based medications in 
1887/88 (2). Non-malignant arsenic-induced diseases include Blackfoot disease, 
a dry gangrene resulting from ischemic changes in the toes accompanied by 
ulcers. Blackfoot disease was first observed in the southwest coastal area of 
Taiwan (18, 19). 
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Several studies showed that arsenic causes genotoxic damage and 
chromosomal abnormalities in lymphocytes, buccal cells, and exfoliated urinary 
bladder cells, which might contribute to arsenic carcinogenesis (20-24). 
Furthermore, unpublished data from the States lab showed that low levels of 
chronic arsenic exposure lead to chromosomal alterations in human 
keratinocytes. Besides chromosomal abnormalities, arsenic causes epigenetic 
alterations including changes in DNA methylation, histone modification and 
microRNA (miRNA) expression (25, 26). Arsenic-induced changes in DNA 
methylation and histone modification are extensively studied (25); however, 
arsenic-induced miRNA alterations are understudied.  
MicroRNAs (miRNAs) 
MiRNAs are part of the epigenome and play a fundamental role in the 
regulation of most mammalian protein codling genes (27). MiRNAs are small, 
noncoding RNAs that play a crucial role during developmental processes, 
apoptosis and cell proliferation, and in regulating translation of most mammalian 
protein-codling mRNAs. In fact, it is estimated that more than 60% of human 
protein-coding genes are targeted by miRNAs (28). Aberrant miRNA expression 
has been associated with development, progression and response to therapy of 
viral, immune-related and neurodegenerative diseases, and cancer (29).  
MiRNA Processing and Regulation of Translation 
The biogenesis of miRNA takes place in both the nucleus and the 
cytoplasm producing 21-25 nucleotide endogenous RNAs. The formation of 
mature miRNA is a two-step process (Fig. 1.1). In the first step, the nascent 
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miRNA transcripts (pri-miRNA) are trimmed by the microprocessor complex 
containing the double-stranded RNA-specific ribonuclease Drosha into pre-
miRNA (~70-nucleotide pre-miRNA hairpin) (30, 31). Then, the trimmed pre-
miRNA is exported from the nucleus to the cytoplasm by exportin 5 where the 
pre-miRNA gets cleaved into ~21–25-nucleotide single-stranded mature miRNA 
by a protein complex consisting of helicase with RNase motif (Dicer) and HIV-
1 TAR RNA binding protein (TRBP) (30, 31). Along with Dicer, TRBP recruits the 
argonaute protein Ago2 and other Ago proteins to initiate assembly of the RNA-
induced silencing complex (RISC), a ribonucleoprotein complex that binds to one 




Figure 1.1. MiRNA biogenesis. The figure illustrates the multiple steps of 
miRNAs biogenesis in both the nucleus and cytoplasm and their role in regulating 
their target mRNAs. 
 7 
MiRNAs target cytosolic mRNA by hybridization to complementary 
sequences, typically in their 3′-untranslated regions (UTRs) called the “seed 
region” leading to decreased translation or deadenylation and degradation of the 
mRNA (32, 33). When miRNAs pair perfectly with their target mRNAs, e.g. the 
seed region of mRNA matches perfectly with the targeting miRNA, that leads to 
the degradation of the mRNA (34). However, imperfect base pairing leads to 
repression of mRNA translation and the possibility of restoring translation once 
the repressor miRNA is degraded (34). Recent studies showed some miRNAs 
also can bind to the 5′-UTR or the open reading frame (ORF) regions (35). 
MiRNAs play a role in all the most important processes in every biological system 
(36). A single miRNA can target hundreds of mRNAs, and the translation of an 
mRNA can be regulated by multiple miRNAs creating complex feedback and 
feed-forward gene regulatory loops in a cell. The regulatory loops provide checks 
and balances within and across gene networks (37, 38).  
MiRNA Role in Carcinogenesis 
MiRNA expression has been found to be aberrant in different cancers, 
including cervical, lung, esophageal, oral, pharyngeal and tongue SCC (39). 
Furthermore, several studies done by the Bechara group demonstrated that the 
expression of Dicer, Drosha and the RISC components in epithelial tumors, such 
as cutaneous SCC (cSCC), were deregulated compared to healthy control 
samples (40, 41). Moreover, several studies have demonstrated the association 
between miRNA expression and tumor development, progression and response 
to therapy, making miRNAs promising potential biomarkers for disease diagnosis 
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and prognosis (35). Furthermore, multiple studies have shown that arsenic can 
alter miRNA expression patterns in arsenic-induced cancers in vitro and in vivo 
(42-45).  
MiRNAs Expression Dysregulation in Arsenic-Induced Cancers 
Arsenic has been associated with a wide range of health problems 
including pregnancy complications and teratogenicity, developmental effects, 
neurotoxicity, diabetes, pulmonary disease, cardiovascular disease, vascular 
disease, skin manifestations and cancers (6, 7). Numerous studies, mostly in 
arsenic-induced cancers, showed that arsenic alters both mRNA and miRNA 
expression patterns (42, 44-50). However, fewer studies examined miRNA 
expression patterns in other arsenic-induced disease such as diabetes mellitus 
(51-59).  
Altered miRNA expression pattern was also reported in multiple studies in 
arsenic-induced human tumors and transformed cell lines (42-45). Several 
studies showed that expression of different miRNA families and miRNAs, e.g., 
the miR-200 and let-7 families and miR-21, was altered with various arsenic 
species and doses in several arsenic-induced tumors and transformed cell lines 
(60). These studies suggest that miRNA expression plays a critical role in 
arsenic-induced tumorigenesis and carcinogenesis. Therefore, longitudinal 
studies following the differential expression throughout the transformation 
process are necessary to evaluate the changes critical to arsenic-associated 
transformation and carcinogenesis.  
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Arsenic-Induced Skin Cancer Models 
There are several animal and cell line models to study arsenic-induced 
cancers. Waalkes et al. established the in utero arsenic exposure model to study 
arsenic-induced transplacental carcinogenesis (61). C3H mice offspring were 
exposed in utero to arsenic through drinking water followed by post-natal 
exposure (61). Multiple arsenic-induced tumors were reported when mice 
became adults except for dermal tumors (61). Thus, there is no established 
rodent model to study skin cancers induced in adult animals by inorganic arsenite 
alone through ingestion, mimicking drinking water exposure (62, 63). Arsenic 
enhanced mutagenicity of skin tumors occurs only in animals co-exposed to 
another tumor promoter such as 12-O-tetradecanoyl phorbol-13- acetate (TPA) in 
transgenic TG.AC mice (carry the v-Ha-ras oncogene) (62) or a carcinogen, such 
as Ultraviolet (UV) light in female hairless mice (Crl: SK1-hrBR) (63).  
There are not many cell line models used for both acute and chronic 
arsenic-induced skin cancer studies. Immortalized cells are needed for chronic 
exposure studies because it is necessary to maintain these cells are maintained 
for an extended time required for transformation. Immortalized human 
keratinocytes (HaCaT) are an in vitro model for normal human keratinocytes that 
can be used to study arsenic-induced skin cancer (39, 64). Pi et al. (2008) 
showed that continuous exposure of HaCaT cells for 28 weeks to a low level 
(100 nM) of sodium arsenite transformed these cells and resulted in an 
aggressive SCC phenotype upon inoculation of nude mice (39). The 
concentration of 100 nM sodium arsenite was selected based on an 
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epidemiological study of a population in China that consumed well water 
containing high concentrations of arsenic. The study subjects were diagnosed 
with chronic arsenic intoxication and arsenic-induced skin lesions and epidermal 
cancers. Thus, 100 nM sodium arsenite is biologically relevant to that circulating 
in the study subjects’ blood (65). The model has also been reported by Sun et al. 
as an important model to study the induction of skin cancer by arsenic exposure 
(66). However, the various stages starting from the early stages of the 
transformation process in this model have not been studied yet. Furthermore, 
there has been no further evaluation for the model as an SCC model as 
suggested by Pi et al. (2008). 
In this work, the differential miRNA expression of arsenic-induced in skin 
cancer in human skin lesions and the differential small RNA and mRNA 
expression in HaCaT cells chronically exposed to arsenic were investigated.  In 
fact, the miRNA expression profiles obtained from the arsenic-induced skin 
lesions are the first to be reported in human arsenic-induced tissues. The results 
obtained from these skin lesions showed that some miRNAs were phenotype 
related, e.g. SCC or BCC, or stage related, e.g. malignancy or metastasis. The 
miRNA and mRNA expression profiles obtained from the HaCaT cells at early 
time points were done using RT-qPCR and hybridization microarrays. The 
complexity of the results’ interpretation required using a more thorough technique 
(Next-Generation Sequencing (NGS)) at later time points (19 and 28) of 
exposure along with 7 weeks for better interpretation. The time points for NGS 
were selected based on the results obtained from RT-qPCR and hybridization 
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microarrays, growth curves of these cells over 32 weeks and reports in the 
literature of the stages of transformation of these cells. 
At early time points (3 and 7 weeks), low arsenite was capable of 
changing the expression pattern of small RNAs along with mRNAs with dramatic 
changes at 7 weeks. Focusing on some miRNAs and mRNAs differentially 
expressed at both of the early time points suggested that the early changes in 
miRNA profiles and their target genes in human keratinocytes contribute to 
arsenic-induced carcinogenesis. Furthermore, low arsenite at 7 weeks induced 
differential gene expression indicating dysregulation of cell cycle control, which 
was confirmed by cell cycle analysis and the slow growth of these cells at the 
early time points.  
The results obtained from NGS showed a greater number of differentially 
expressed small RNAs and mRNAs after 19 weeks arsenite exposure compared 
to both 7 and 28 weeks. The results confirmed that most of the transformation 
related changes happen between 19 and 20 weeks of low arsenite exposure as 
suggested in the literature (66). Moreover, in this work, the chronic exposure 
HaCaT cell model was also evaluated as an SCC model. Comparing the miRNA 
profiles of HaCaT cells and skin lesions showed that the HaCaT chronic 
exposure model is closer to being an arsenic-induced SCC than BCC model as 
suggested by Pi et al. (39). 
The study suggests that miRNAs play an important role in the 
mechanisms that contribute to arsenic-induced carcinogenesis and skin cancer in 
particular. Furthermore, the results suggest that some of the miRNAs we 
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described could be considered as potential biomarkers or therapy targets for 
arsenic-induced internal cancers.  
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CHAPTER 2 
MIRNA EXPRESSION PROFILES OF PREMALIGNANT AND MALIGNANT 
ARSENIC-INDUCED SKIN LESIONS  
Introduction 
Arsenic is a naturally occurring element that is prevalent in the earth’s 
crust (67). Exposure to arsenic in drinking water is a worldwide problem and 
more than 200 million people consume water contaminated with arsenic above 
the World Health Organization (WHO) recommended limit (10 μg/L, in 2008) (68, 
69). According to the WHO, exposure to levels of arsenic exceeding the safe limit 
for more than six months leads to arsenicosis (12). The major areas where a 
large number of people are exposed to high levels of arsenic in drinking water 
are mainly in South Asia (Bangladesh, India, Nepal, Cambodia, Viet Nam, 
Taiwan) and Latin America (Argentina, Bolivia, Chile, Mexico) and to a lesser 
extent in the U.S.A. (5, 11, 70-79). The Ganges River delta spanning West 
Bengal in India and Bangladesh has been struggling for decades with the largest 
mass poisoning in human history from arsenic contaminated drinking water 
coming from natural sources (5, 80). More than 70 million people in 
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the delta area consume highly arsenic contaminated drinking water and have 
high-risk of arsenicosis and a wide range of chronic arsenic exposure-associated 
health complications such as pregnancy complications and teratogenicity, 
developmental effects, neurotoxicity, diabetes, pulmonary disease, 
cardiovascular disease, skin manifestations and cancers (7, 80, 81). Non-
malignant arsenic-induced diseases also include Blackfoot disease, a dry 
gangrene resulting from ischemic changes in the toes accompanied by ulcers 
(18, 19). Arsenic has been classified for more than 15 years by the International 
Agency for Research on Cancer (IARC) as a Group 1 human carcinogen and 
Group A by the United States Environmental Protection Agency (U.S. EPA) (7). 
Chronic arsenic exposure causes multiple cancers including those of skin, 
bladder and lung, and to a lesser extent, liver, kidney, and prostate (82). 
Skin cancer is the most prevalent form of all cancers (9). Most skin 
cancers are a consequence of mutations resulting from DNA damage caused by 
the ultraviolet radiation in sunlight (10). The second most frequent cause of skin 
cancer is chronic arsenic exposure. The skin is the primary target organ for 
arsenic toxicity. In populations exposed to high levels of arsenic in their drinking 
water and food, arsenic is a leading cause of skin cancer (11, 12). Arsenic-
induced skin toxicity symptoms first appear as pigmentary changes including 
raindrop-shaped lesions and diffuse dark brown lesions followed by arsenical 
keratosis in the palms, soles and trunk, and multiple cutaneous malignancies 
(13-16).  
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Arsenic-induced skin cancer has a different pattern of pathology and 
progression to malignancy compared to sunlight-induced skin cancer. Actinic 
keratoses are the premalignant lesions for sunlight-induced SCC while arsenical 
hyperkeratoses are premalignant lesions of both BCC and SCC in arsenicosis 
(Fig.2.1) (83, 84). 
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Figure 2.1. Skin Cancer Progression. Progression from the premalignant lesion 
HK to either of the malignant lesions, BCC directly or SCC through BD (SCC in 
situ). Shown are photographs of lesions in situ prior to excision with a histological 
section of the formalin fixed and paraffin embedded sample stained with 
hematoxylin and eosin on the right.   
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Moreover, sunlight causes SCC, BCC and malignant melanoma whereas 
arsenic exposure does not cause malignant melanoma (83, 84). Keratosis or 
hyperkeratosis in body areas not exposed to the sun is the most distinguishing 
cutaneous manifestation of arsenicosis (18). Arsenical keratoses are 
characterized by pathological features such as hyperkeratosis, parakeratosis, 
arsenical pigmentation, and SCC in situ at a later stage (13). Keratoses’ color is 
usually the skin color or darker and the size is dependent on the disease 
progression stage, larger lesions generally are more severe (18). The presence 
of dysplasia in the keratotic lesions is an intermediate stage between 
premalignancy and malignancy and histological characterization can be 
challenging. Dysplastic keratoses are immediate predecessors to BD and SCC. 
Chronic arsenic exposure also causes BD, which is SCC in situ (18). BD and 
superficial BCC are the most common malignant lesions in arsenicosis (18). BCC 
is not invasive whereas SCC is a true invasive carcinoma and it tends to 
progress in later stages of arsenic exposure (13, 18). Individuals can have one or 
several types of skin lesions simultaneously (18).  
The mechanisms of arsenic-induced carcinogenesis are not yet clear and 
there are several proposed mechanisms including epigenetic alterations. 
miRNAs are part of the epigenome and play a fundamental role in the regulation 
of most mammalian protein codling genes (27). miRNAs are a family of small 
noncoding RNAs between 21 and 25 nucleotides in length (27). To add to the 
complexity of miRNAs’ role in regulating gene expression, one miRNA can target 
several mRNAs and an individual mRNA can be targeted by multiple miRNAs 
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creating complex regulatory loops in a cell establishing a balance across gene 
networks (37, 38). Furthermore, the association between miRNA expression and 
tumor development, progression and response to therapy have been discussed 
in several studies presenting miRNAs as potential biomarkers for disease 
diagnosis and prognosis (35). The study presented in this chapter helps in 
understanding the association between miRNA expression and arsenic-induced 
skin lesion development and progression, and in obtaining hallmarks of 
development and progression at different stages of the carcinogenic process. 
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Materials and Methods 
a. Sample Collection Criteria and Diagnosis 
Skin lesion samples were obtained as 2 mm skin punch biopsies from 
tumors and lesions excised for diagnostic purposes from subjects visiting field 
hospitals in the Murshidabad district of West Bengal, India. Samples were 
collected with informed consent provided in native language with approval of the 
Ethical Committee on Human Subjects at Indian Institute of Chemical Biology 
and the Institutional Review Board at University of Louisville. The samples were 
fixed in formalin (light fixation) and embedded in paraffin (FFPE). Gross 
diagnosis of the samples was performed by dermatologists at the time of lesion 
excision and confirmed in Louisville histopathologically by a dermatopathologist 
examining thin sections stained with hematoxylin and eosin (H&E).  
b. Laser Capture Microdissection System (LCM) 
Keratinocytes were isolated from 7 μm sections of samples using an 
ArcturusXT™ Laser Capture Microdissection System (LCM). The sectioned 
tissues were first deparaffinized and stained using the Arcturus Paradise Plus 
staining kit and the isolated cells were collected on macrocaps. Total RNA was 
purified from the tissues on the macrocaps using Arcturus Paradise Plus FFPE 
RNA extraction and Isolation Kits. Total RNA quality and quantity were 
determined using the Agilent RNA 6000 Pico Kit, Eukaryote, version 2.6 and the 
Agilent 2100 Bioanalyzer instrument (Agilent Technologies, Inc., Santa Clara, 
CA, USA). Total RNA (50-100 ng) from each sample was reverse transcribed 
 20 
and pre-amplified to prepare cDNA using RT kit, MegaPlex Primers and Pre-Amp 
kit (Life Technologies) following the Megaplex™ Pools For microRNA Expression 
Analysis protocol with preamplification.  
c. miRNA RT-qPCR array Cards 
Profiling miRNA expression was performed using the TaqMan® Array 
Human MiRNA A Card v2.0 (polymerase chain reaction (RT-qPCR) array cards, 
Life Technologies). The array measures the expression of 384 targets; 377 
miRNAs and 7 controls. Four of seven controls are U6 RNA, the mean of which 
was used for normalization in our dataset.  The data were collected at 0.1 
threshold value on an Applied Biosystems ViiA7 Real Time PCR System. The Ct 
values were normalized to the mean of Ct values of U6 RNA (ΔCT method).  
d. Statistical analysis 
The ΔCt values were calculated using the Ct values of the miRNAs from 
premalignant or malignant lesions and normalizing them to the means of the Ct 
values of the reference RNA U6. Statistical analyses were performed by 
comparing the ΔCt values of the premalignant and malignant lesions using one-
way ANOVA by SAS System V9. Cary, NC: SAS Institute Inc, 2003.  
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Results 
a. Study Population Demographics and Histopathological Analysis  
The subjects were exposed to high levels of arsenic in their drinking water 
(51 to 398 ppb; mean 106.4 ± 63.9, Table 2.1), which is similar to well water 
arsenic levels seen in the northeastern and southwestern United States (85-87). 
The samples were collected from 35 males (25-60 years old) with urine arsenic 
levels ranging from 100 to 1,590 μg/L (mean 299.3 ± 281.9). The subset from 
which miRNAs in lesions were analyzed had narrower ranges of age, water and 
urine arsenic (47 ± 3.9, 92.7 ± 41.3, 335.8 ±  324.9 respectively, Table 2.1). 
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Table 2.1. Demographics of study population. 





14E HK M 50 91.1 240 
28E* HK M 40 61.5 140 
19D# HK M 50 59.8 417 
28B* SCC M 40 61.5 140 
26A# SCC M 50 59.8 417 
18B$ SCC M 45 79.8 100 
8A$ BCC M 45 79.8 100 
17A BCC M 49 172 958 
20C BCC M 48 92 160 
*, # and $ indicate samples from the same individual. 
 23 
The skin lesions were histologically complex, often containing 
inflammatory infiltrates, thus requiring histopathologic identification of 
keratinocytes to be isolated for RNA analyses. Inflammatory infiltrates were 
commonly observed in BCC (Fig. 2.2.A) and SCC (Fig. 2.2.B) samples. Many of 
the lesions classified as hyperkeratosis on gross examination contained regions 
of dysplasia often appearing to be early Bowen’s disease (Fig. 2.2.C). Thus, the 
histological diagnosis of the samples was critical, and the HK samples were 
divided into 2 groups based on histology. The first group included those lesions 
showing dysplasia and were excluded from analysis (Fig. 2.2.C). The second 
group included samples which showed no signs of dysplasia (true premalignant 
lesions, Fig. 2.2.B). HK, which showed no signs of dysplasia (true premalignant 
lesions), were selected for further processing. The BCC and SCC or BD samples’ 
gross diagnoses also were confirmed histologically. Keratinocytes were 
harvested from each sample using LCM. LCM technology permitted microscopic 
precision and the ability to harvest exclusively pathology-proven diseased tissue 
from biopsy samples while excluding undesired dysplastic cells, or adjacent 
inflammatory and other nonkeratinocyte tissues. Most samples yielded too little 
RNA for analysis. Three samples of each lesion type (HK, BCC, SCC) yielded 






















Figure 2.2. Arsenic induced premalignant and malignant skin lesions. 
Histological sections of arsenic-induced basal cell carcinoma, squamous cell 
carcinoma and hyperkeratosis. A. Basal cell carcinoma, arrows point to 
inflammatory foci. B. Squamous cell carcinoma, arrows point to inflammatory 
foci. C. Hyperkeratosis with dysplasia, arrows point to areas of dysplasia 
projecting from the hyperkeratotic region. D. Hyperkeratosis without dysplasia.  
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b. miRNA Profiles in Premalignant and Malignant HK, BCC and SCC Lesions 
Differential miRNA expression profiles were obtained by comparing 
expression in three premalignant HK lesions and six malignant lesions (3 SCC 
and 3 BCC). One-way ANOVA analysis of ∆Ct values (vs U6 RNA) indicated that 
thirty-five miRNAs were differentially expressed among the three lesion types 
analyzed (Fig. 2.3, Table 2.2). Differential expression fell into six classifications 
(Table 2.2). Two miRNAs were induced in both BCC and SCC relative to HK 
(Fig. 2.3.A, Table 2.2), e.g. these miRNAs were associated with malignancy in 
general. Two other miRNAs were induced in SCC relative to both BCC and HK 
(Fig. 2.3.B, Table 2.2), e.g. these were selectively induced in the tumors capable 
of metastasis. Six miRNAs were selectively suppressed in BCC relative to both 
SCC and HK (Fig. 2.3.C, Table 2.2). A fourth group of three miRNAs were 
differentially expressed in BCC relative to HK, but expression in SCC was not 
different from either BCC or HK (Table 2.2). A fifth group of three miRNAs were 
differentially expressed in SCC relative to HK, but expression in BCC was not 
different from either SCC or HK (Table 2.2). The sixth group contained eight 
miRNAs induced in SCC relative to BCC, but not differentially expressed in HK 
relative to either SCC or BCC.  
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Figure 2.3: Differentially expressed miRNA in Arsenic-induced Skin 
Lesions. Selected differential expression comparisons are diagramed. 
Differentially expressed miRNAs in (A) malignant lesions, both BCC and SCC 
relative to HK; (B) Specifically in SCC vs HK or BCC.; (C) Specific to BCC vs 
SCC or HK. Direction of expression changes indicated by arrows. Additional 
differentially expressed miRNAs are listed in Table 2.2. 
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Table 2.2: Differentially expressed miRNAs in Arsenic-induced Skin Lesions 
and Their Expression Reported in Other Types of Human Cancers. 
miRNA 
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Ultraviolet light in sunlight is the most common cause of skin cancer. 
Exposures have a cumulative mutagenic effect on cellular DNA. Carcinogenesis 
has been demonstrated when cellular function is disturbed by mutations in tumor 
suppressors, oncogenes, transcription factors, and nucleotide excision repair 
proteins (254). Chronic arsenic exposure is the second most common cause of 
skin cancer. The mechanism(s) of arsenic-induced skin cancer is not completely 
characterized, but evidence suggests that mutations are not the main driving 
force (255, 256). Other pathways have been hypothesized including DNA repair 
inhibition, cell cycle pathway dysregulation and epigenetic modification including 
histone acetylation, methylation and phosphorylation, and miRNA expression 
alterations (25, 26, 257-259). In particular, dysregulation of miRNA expression 
has been implicated in a wide variety of cancers (260). 
In the current chapter, the potential role of dysregulation of miRNA 
expression in arsenic-induced carcinogenesis was investigted. Differential 
miRNA expression was characterized in human arsenic-induced skin lesion 
samples collected from individuals exposed to high levels of arsenic in their 
drinking water. An important observation is that the histopathology of the 
samples revealed potential confounding characteristics of the lesions especially 
for the premalignant arsenic-induced skin lesions. The histological diagnosis of 
the HK samples was critical because many of HK samples showed dysplasia 
with some even resembling early Bowen’s disease. These samples were 
excluded from the miRNA analyses. However, three HK lesions with no signs of 
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dysplasia were selected for further processing and their profiles were compared 
to malignant BCC and SCC lesions. The age of the samples resulted in loss of 
RNA integrity reducing yield. Many samples yielded insufficient amounts for the 
RT-qPCR array analysis. Thus, a weakness of the current study is the small 
number of samples analyzed. In spite of this limitation, miRNA expression 
profiles distinguishing the malignant BCC and SCC from the premalignant HK 
were obtained.  
The results showed differential expression of 35 miRNAs in the 
premalignant and malignant lesions. Some of differentially expressed miRNAs 
were lesion or stage specific. For example, expression of miRNAs miR-425-5p 
and miR-433 was higher in both BCC and SCC relative to HK, with no significant 
difference in expression between SCC and BCC. This result suggests that 
increased expression of miR-425-5p and miR433 is associated with malignancy 
progression from premalignant lesions (Table 3, Fig. 4A.). Consistent with this 
suggestion, miR-425-5p is an intronic miRNA embedded within the DALRD3 
(DALR anticodon binding domain containing 3 gene) and has been reported to 
be induced in metastatic gastrointestinal cancers such as gastric and colorectal 
cancer and possibly associated with melanoma (88-90). MiR-433 is embedded 
antisense within RTL1 (retrotransposon Gag like 1) and studies have shown that 
it is associated with poor progression-free survival in high-grade serous ovarian 
cancer patients (91). MiR-433 also is induced in liver cancer (92) and metastatic 
bladder cancer (94) suggesting it is acting as an oncogene, but it is suppressed 
in gastric cancer suggesting it is functioning as a tumor suppressor in 
 35 
pathogenesis of this cancer type (93). Thus, the role of miR-433 may be context 
specific. 
Similarly, two miRNAs, miR-184 and miR-576-3p, were induced in SCC 
relative to BCC and HK suggesting that the increased expression is associated 
with the invasive and metastatic phenotype of SCC (Table 3, Fig. 4B.) (13). MiR-
184 is embedded antisense to  ANKRD34C-AS ( ANKRD34C antisense RNA 1) 
and was reported to be induced in several squamous cell carcinomas including 
tongue SCC (97) and head and neck squamous cell carcinoma  (100), glioma 
(99), invasive breast cancer (102), hepatocellular carcinoma (108, 109), and in 
sebaceous carcinomas vs. adenomas (104). MiR-184 was reported to be 
suppressed in prostate carcinoma (96), breast cancer (98), neuroblastoma (101), 
epithelial ovarian cancer (103), non-small cell lung cancer (105) and small cell 
lung cancer (106), and renal cell carcinoma (107).  Thus, a role as oncogene or 
tumor suppressor also may be context specific. MiR-576-3p is an intronic miRNA 
embedded within SEC24B (SEC24 homolog B, COPII coat complex component 
gene) and is suppressed in bladder cancer, T-cell precursor acute lymphoblastic 
leukemia, and sera of non-melanoma skin cancer patients (BCC and SCC, UV 
light related) (Balci et al. 2016; Coskun et al. 2013; Z Liang et al. 2015). Thus, 
the role of miR-578 is unclear at this time. 
Six miRNAs (miR-29c, miR-381, miR-452, miR-487b, miR-494 and miR-
590-5p) were suppressed in BCC relative to both SCC and HK suggesting that 
their suppression is BCC phenotype specific (Table 3, Fig. 4C). MiR-29c is 
embedded within last exon of C1orf132 (chromosome 1 open reading frame 
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132), the transcript of which encodes an unknown open reading frame. MiR-29c 
was found induced in non-small cell lung cancer (261). However, consistent with 
its suppression in BCC, miR-29c was reported to be suppressed in several 
cancers including bladder cancer, esophageal squamous cell carcinoma, gastric 
cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung 
adenocarcinoma, nasopharyngeal carcinoma, high-metastatic lung cancer, 
pancreatic cancer and glioma (113-121, 123). MiR-381 and miR-487b were both 
suppressed in BCC. These miRNAs, along with four other miRNAs (miR-539, 
miR-889, miR-544a, miR-655), are part of the MIR381 host gene (MIR381HG). 
These other four miRNAs are all 3’ of miR-381 and miR-487b and were not 
differentially expressed among our HK, BCC and SCC samples. Although miR-
381 was reported to be induced in osteosarcoma and glioma, consistent with our 
observation of suppression in BCC miR-381 was suppressed in several other 
cancers including oral squamous cell carcinoma, epithelial ovarian cancer, 
hepatocellular carcinoma, colorectal cancer, gastric cancer, breast cancer, renal 
cell cancer, colon cancer and lung adenocarcinoma (124-133). Likewise, we saw 
that miR-487b-3p was suppressed in BCC and it has been reported as 
suppressed in colon cancer, high-risk neuroblastoma, pediatric glioma and 
metastatic prostate cancer (144-147). MiR-452-5p is embedded in an intron of 
GABRE (gamma-aminobutyric acid type A receptor epsilon subunit gene) and 
was suppressed in BCC. As for several other miRNAs suppressed in BCC, miR-
452-5p was induced in several malignancies (hemangiosarcoma, clear cell renal 
cell carcinoma and bladder cancer), but found to be suppressed in several other 
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cancers and sarcomas (lung adenocarcinoma, chondrosarcoma, gliomas, 
osteosarcoma, non-small cell lung cancer, prostate cancer and head and neck 
adenoid cystic carcinoma vs. head and neck squamous cell carcinoma) (134-
143). MiR-494 is one of a cluster of five miRNAs on Chromosome 14, but only 
miR-494-3p was found to be differentially expressed in HK, BCC or SCC.  
Contrary to our finding of it being suppressed in BCC relative to SCC and HK, 
miR-494 is induced in several cancers (malignant breast cancer, esophageal 
squamous cell carcinoma, gastric carcinoma, oral cancer, ovarian cancer and 
pancreatic cancer) (148-157). Rather than inferring its suppression in BCC, 
perhaps it is induced early in the transformation of keratinocytes to SCC. MiR-
590-5p is embedded in EIF4H (eukaryotic translation initiation factor 4H gene). 
Like several other miRNAs found suppressed in BCC, miR-590-5p was found to 
be induced in several cancers (cervical cancer, gastric cancer, vulvar squamous 
cell carcinoma, renal cell carcinoma) and suppressed in others (malignant 
melanoma, breast cancer, colorectal cancer) (158-164). Thus, the weight of 
evidence suggests that these miRNAs suppressed in BCC likely are tumor 
suppressors. This inference is supported by the observation by others that these 
miRNAs are suppressed in a wide variety of other tumor types.  
The three miRNAs with the highest fold change in SCC relative to HK and 
BCC were miR-520f and miR-184 (both induced) and miR-127-5p (suppressed) 
with fold changes of 7973,1373 and 207965 respectively (Table 2, Supp. Table 
1). MiR-520f is an intergenic miRNA located on Chromosome 19. MiR-520f was 
found to be induced in glioblastoma tumor cells and suppressed in gastric 
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carcinoma and neuroblastoma (247-249). In this data set, miR-520f was induced 
in SCC relative to BCC lesions suggesting its possible association with invasive 
properties of SCC. However, a study on PANC-1 cells (human pancreatic 
carcinoma cell line) showed that overexpressing miR-520f lead to reversing 
epithelial-to-mesenchymal transition exerting anti-invasive and antimetastatic 
effects (262). Thus, the potential role of miR-520f in arsenic-induced SCC is 
unclear. A study by Wong et al. on tongue SCC cell lines suggested that miR-184 
is an oncogenic miRNA or an “oncomir” (97). The study showed that the 
inhibition of miR-184 leads to reducing cell proliferation and increasing apoptosis 
in three tongue SCC cell lines (97). MiR-184 was induced in our SCC samples 
compared to both HK and BCC samples suggesting that it is an oncomir that may 
also play a role in cell invasion considering the invasive nature of SCC tumors. 
MiR-127-5p was found suppressed in breast cancer, gastric cancer, 
hepatocellular carcinoma and colon cancer patients’ stool (Supp. Table 1) (93, 
177-179). These results suggest that miR-127-5p is a tumor suppressor. MiR-
127-5p was suppressed only in our SCC samples suggesting that it is maybe 
more relevant to the invasive properties of SCC tumors. This suggestion is 
supported by a study showing that miR-127-5p suppresses MMP-13 and IL-1β 
responses in human chondrocytes and the decreased expression of miR-127-5p 
enhances the progression of cartilage destruction (263). 
Not only does arsenic driven skin cancer have a different pattern of 
pathology and progression to malignancy than sunlight-induced skin cancer, but 
also different miRNA expression profiles. The miRNA expression of miR-576-3p 
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reported by Balci et al. for sunlight-induced BCC and SCC is not reflected in the 
miRNA expression profiles of arsenic-induced BCC and SCC in the current study 
(111), providing further support for the difference in etiology between arsenic-
induced and sunlight-induced skin cancers.  
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CHAPTER 3 
DIFFERENTIALLY EXPRESSED MIRNAS AND MRNAS AT EARLY STAGES 
OF TRANSFORMATION OF HACAT CELLS CHRONICALLY EXPOSED TO 
LOW ARSENITE   
Introduction  
Several arsenic toxicity and carcinogenicity mechanisms have been 
suggested and proposed including abnormal signaling cascades, oxidative 
stress, and chromosomal aberrations as well as abnormal transcriptional activity 
and global gene expression (264). Moreover, arsenic can induce 
environmentally-driven epigenetic alterations that are known to influence disease 
development, including differential miRNA expression (265, 266). MiRNAs play a 
role in all the most important processes in every biological system (36). A single 
miRNA can target hundreds of mRNAs, and the expression of a gene can be 
regulated by multiple miRNAs creating complex feedback and feed-forward gene 
regulatory loops in a cell. MiRNAs target mRNAs by hybridization to 
complementary sequences in their 3′-untranslated regions (UTRs) and repress 
translation (267). Recent studies on some miRNAs showed they also can bind to 
the 5′-UTR or the open reading frame (ORF) region (35). The regulatory loops 
provide checks and balances within and across gene networks (37, 38).  
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Several studies have shown that differential miRNA expression can be a 
hallmark of cancer and miRNAs can function as potential oncogenes or tumor 
suppressor genes influencing tumor development, progression and response to 
therapy (35, 268). MiRNAs exhibit differential expression in different cancers, 
including cervical, lung, esophageal, oral, pharyngeal and tongue squamous cell 
carcinoma (39). Furthermore, dysregulation of several miRNAs, including miR-
21, miR-200a, miR-141 and let-7c, has been reported in HaCaT cells after acute 
or sub-chronic exposure to moderate levels of arsenic (47, 265). 
HaCaT cells are a spontaneously immortalized human epithelial cell line 
established in 1988 from adult human skin (64). HaCaT cells are an in vitro 
model for normal human keratinocytes and are commonly used to study 
epidermal carcinogenesis (269). HaCaT cells malignantly transformed by chronic 
incubation in low concentration of sodium arsenite (66) are the only currently 
available in vitro model to study arsenic-induced skin carcinogenesis (185, 270-
274). However, miRNA expression profiling has never been obtained in human 
keratinocytes chronically exposed to low arsenic (100 nM). This chapter is 
focused on understanding the role of differentially expressed miRNA and their 
target genes. For broad detection coverage, hybridization microarrays were used 
to measure mRNAs and small RNAs differentially expressed at the early stages 
of arsenic-induced skin cancer using HaCaT cells exposed to 100 nM NaAsO2 for 
3 and 7 weeks. TP53 and PTEN regulatory pathways were also found 
dysregulated, offering a potential means for suppression of these tumor 
suppressors in lieu of mutation playing a role in arsenic induced skin 
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carcinogenesis. Moreover, the current chapter discusses the growth curves of 
the HaCaT cell chronic arsenic exposure model. The growth pattern of the cells 
changed over the different stages of exposure till reaching transformation. 
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Materials and Methods: 
a. Cell Culture and RNA Isolation 
HaCaT cells were the kind gift of Dr. TaiHao Quan, University of Michigan. 
The cells were cultured in MEM alpha modification media supplemented with 
10% fetal bovine serum, 100 units/mL penicillin/100 µg/mL streptomycin) and 2 
mM glutamine. Cultures were maintained at 37°C in a humidified 5% 
CO2 atmosphere. Multiple cultures of cells (4 with and 4 without 100 nM NaAsO2) 
were maintained separately for 32 weeks. Cells were passaged twice a week and 
a million cells were plated per 100 mm dish every time. At each passage, the 
cells were counted and population doublings were calculated along with the 
means ± SD of cumulative doubling. Statistical analysis was performed by two-
way ANOVA, p-value ≤0.05 was considered significant.  
NaAsO2 (CAS 7784-0698) was obtained from, Fisher Scientific, Waltham, 
MA, USA. Total RNA was purified from the cells (quadruplicate unexposed and 
exposed cultures) after 3, 7, 19 and 28 weeks using the mirVana™ RNA Isolation 
Kit (Thermo Fisher Scientific Inc., Waltham, MA, USA). RNA quality was 
determined using the Agilent RNA 6000 Pico Kit, Eukaryote, version 2.6 and the 
Agilent 2100 Bioanalyzer instrument (Agilent Technologies, Inc., Santa Clara, 
CA, USA). All samples used had RIN (RNA integrity number) > 9.  
b. Hybridization Microarray Analysis 
Expression profiles of mRNA and small RNA were obtained for HaCaT 
cells exposed to arsenite for 3 and 7 weeks using the GeneChip® PrimeView™ 
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Human Gene Expression and GeneChip® miRNA 4.0 Affymetrix arrays. The 
former, used for measuring mRNA expression, contains more than 530,000 
probes that detect over 36,000 transcripts and variants, representing over 20,000 
genes mapped via RefSeq or via UniGene annotation. The latter probes for small 
non-coding RNA transcripts: 100% miRBase v20 coverage, 30,424 mature 
miRNA (all organisms), 5,214 human, mouse, and rat miRNA, 1,996 human 
snoRNA, scaRNA and 3,770 probe sets unique to human, mouse, and rat pre-
miRNA hairpin sequences including three types of small RNAs, snoRNAs, and 
both stem-loop and mature miRNAs. Biotinylated cRNA was prepared according 
to the standard protocol for Affymetrix 3' IVT Express Plus Reagent Kit from 250 
ng total RNA. Following fragmentation, cRNA was hybridized for 16 h at 45°C to 
Affymetrix Primeview Human arrays according to the Affymetrix GeneChip 3' 
array Hybridization User Manual. GeneChips were scanned using GeneChip 
Scanner 3000 7G (Affymetrix) and the GeneChip Command Console 4.0 
(Affymetrix). For miRNA 4.0 arrays, biotinylated RNAs were prepared according 
to the standard protocol for Affymetrix FlashTag Biotin HSR RNA labeling Kit 
from 800 ng total RNA. Biotin-labeled samples were hybridized for 18 h at 48 °C 
to Affymetrix miRNA 4.0 arrays. GeneChips were scanned using GeneChip 
Scanner 3000 7G (Affymetrix) and the GeneChip Command Console 4.0 
(Affymetrix). The CEL files were imported into Partek software Version 6.6 
(Partek Inc) and normalized using Robust Multi-Array (RMA) normalization. 
Contrasts of interest were analyzed using a 2-way ANOVA considering treatment 
and time. Using Partek Genomic Suite™, potential targets of 6 of 19 differentially 
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expressed miRNAs (p-value ≤ 0.05) at both 3 and 7 weeks were obtained from 
the TargetScanHuman 6.2 database (2450 genes). Intersecting the target mRNA 
list with the differentially expressed mRNA lists at both 3 and 7 weeks (323 
mRNAs, p-value ≤ 0.05), we obtained a list of differentially expressed mRNAs 
that are potential targets of differentially expressed miRNAs at both 3 and 7 
weeks based on having the same probe annotation number on GeneChip (Fig. 
3.2). Data have been deposited in the GEO database, accession number102 
GSE97306. 
Most of miRNAs lead the RNA-induced silencing complex (RISC) to the 3' 
UTRs of their mRNA targets causing degradation or inhibiting translation of the 
mRNAs (34, 275). Using this approach, we obtained a lists of differentially 
expressed target mRNAs at 3 weeks and 7 weeks with expression direction 
opposite to that of the targeting miRNAs (differentially expressed miRNAs at 3 
weeks, p-value ≤ 0.05), e.g. induced mRNA targets for suppressed miRNA and 
vice versa. 
c. Immunoblotting: 
Total protein was extracted from the cells (quadruplicate unexposed and 
exposed cultures) after 7 weeks using Lysis solution  (0.01 M Tris-HCl pH 7.4, 1 
mM EDTA, 0.1 % SDS, 180 µg/mL PMSF and 1X protease inhibitor cocktail 
(Complete, Roche, Mannheim, Germany)). Lysates were sonicated and protein 
concentrations were measured using the BCA assay kit (Sigma-Aldrich, BCA1 
and B9643). Proteins were resolved by electrophoresis using Bio-Rad 4–15% 
Mini-PROTEAN® TGX™ Precast Protein gels. Gels were electrotransferred onto 
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cellulose nitrate (wet transfer). Membranes were blocked using 5% skim milk in 
Tris-buffered saline containing 0.1% Tween-20 (TBS-T) for 2 h, then incubated at 
4ºC overnight with the following antibodies diluted in 5% (w/v) BSA in TBS-T: 
rabbit mAb anti-HMG1 (D3E5) (6893S) (Cell Signaling Inc, Danvers, MA) (1:800), 
mouse monoclonal anti-MDM2 (Santa Cruz Biotechnology, Inc., Dallas, TX.) 
(1:800), rabbit polyclonal anti-TP53 (#9282) (1:650), rabbit polyclonal anti-
Phospho-p53 (Ser15) (1:800) and rabbit polyclonal anti-Acetyl-p53 (Lys382) 
(1:800) (Cell Signaling Inc, Danvers, MA), followed by an anti-rabbit (for anti-
HMG, anti-TP53, anti- Phospho-p53, anti- Acetyl-p53) and anti-mouse (for anti- 
MDM2) secondary antibodies conjugated with horseradish peroxidase (Cell 
Signaling, 7074 and 7076 respectively) (1:3000). PageRuler Plus Prestained 
Protein Ladder #26619 (Thermo Fisher Scientific, Waltham, MA) was used as a 
molecular weight marker. β-Actin was used loading control using . Antibody 
reactive bands were detected using Pierce™ ECL Plus kit (Thermo Scientific, 
32132). Imaging and quantitation was done using ImageQuant™ LAS 4000 
biomolecular imager (GE Healthcare Life Sciences, Pittsburgh, PA). Two-tailed 
Student T-Test was used for statistical analyses. 
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Results 
a. Growth Rates of Arsenite Exposed Cells were Slower at Earlier Times and 
Faster at Later Times 
At each passage, the population doublings were calculated and the means 
± SD of cumulative doubling were plotted (Fig. 3.1). The results showed that 
growth rates of arsenite exposed cells were slower at earlier times prior to 19 
weeks then the growth curve shifted and the cells grew faster at later times.  
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Figure 3.1. Impact of arsenite exposure on cumulative HaCaT cell 
population doubling. Quadruplicate HaCaT cell cultures were incubated with 0 
or 100 nM NaAsO2. Population doublings were calculated and the means ± SD of 
cumulative doubling at each passage were plotted. Growth rates of arsenite 
exposed cells were slower at earlier times and faster at later times. Statistical 
analysis was done by two-way ANOVA, *p ≤0.05 
.
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b. Arsenite-dependent small RNA and mRNA differential expression: 
Samples of RNA purified from quadruplicate cultures of exposed and 
unexposed HaCaT cells at 3 and 7 weeks of arsenite exposure were analyzed by 
hybridization to miRNA 4.0 Affymetrix microarrays. The results showed that 293 
and 373 small RNAs were differentially expressed respectively after 3 and 7 
weeks exposure to 100 nM sodium arsenite (p-value ≤ 0.05) (Fig. 3.2.A). 
Nineteen small RNAs were differentially expressed at both time points and 
included 8 snoRNAs, 5 stem-loop miRNAs (miR-339, miR-1228, miR-4309, miR-
4692, miR-548au) and 6 mature miRNAs (miR-548a-3p, miR-2682-5p, miR-
3618, miR-8083, miR-1254, miR-645) (Table 3.1). Unsupervised hierarchical 
clustering of these 19 small RNAs showed exposure-dependent differential 
expression of 12 small RNAs with 4 increased and 8 decreased compared to 
unexposed cells at both time points (Fig. 3.2.B). Time-dependent differential 
expression was observed for 6 small RNAs and this differential expression was 
reversed by arsenite exposure (Fig. 3.2.C). Analysis of mRNA expression 
revealed that 1197 and 4840 mRNAs were differentially expressed after 3 and 7 
weeks exposure to 100 nM sodium arsenite (p-value ≤ 0.05), respectively, and 
323 mRNAs were differentially expressed at both time points (Fig. 3.2.D) 
.
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Figure 3.2. Exposure and time-dependent Differential Expression of Small 
RNAs and mRNAs detected by hybridization microarrays. A) Venn diagrams 
of differentially expressed small RNAs at both 3 and 7 weeks (p<0.05). B,C) 
Unsupervised hierarchical clustering of the 19 small RNAs differentially 
expressed at both 3 and 7 weeks of exposure to arsenite. B) Arsenite exposure-
dependent induced (red boxed) and suppressed (green boxed) small RNAs. C) 
Time-dependent differentially expressed miRNAs and the expression pattern is 
flipped by arsenite exposure compared to non-exposed cells, induced (red 
boxed) and suppressed (green boxed). D) Venn diagram of differentially 
expressed mRNAs at 3 and 7 weeks. E) Predicted mRNA targets of 6 
differentially expressed miRNAs were found in TargetScan Human V6.2 
database. F) Venn diagram of intersection of predicted mRNA targets of 
differentially expressed miRNAs and differentially expressed 323 mRNAs at both 
3 and 7 weeks. G,H) Unsupervised hierarchical clustering of the 39 mRNAs 
differentially expressed at both 3 and 7 weeks of exposure to arsenite that are 
predicted targets of 6 miRNAs differentially expressed at both 3 and 7 weeks. G) 
Arsenite exposure-dependent induced (red boxed) and suppressed (green 
boxed) mRNAs. H) Time-dependent differentially expressed mRNAs and the 
expression pattern is flipped by arsenite exposure compared to non-exposed 
cells, induced (red boxed) and suppressed (green boxed). Analysis was done 
using Partek Genomic Suite™. 
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Table 3.1. Differentially expressed small RNAs at both 3 and 7 weeks of 
exposure to arsenite 
# 











1.  14qII-1 CDBox 
(sub-type 
of snoRNA) 
-1.197 0.04363 -1.296 0.00691 
2.  ENSG00000212338 snoRNA -1.246 0.02753 1.241 0.02979 
3.  ENSG00000221345 snoRNA -1.132 0.01756 1.148 0.00968 
4.  ENSG00000221496 snoRNA 1.187 0.00091 1.109 0.02166 
5.  ENSG00000238611 snoRNA -1.070 0.02915 -1.121 0.00132 
6.  ENSG00000238807 snoRNA -1.351 0.00779 1.307 0.01494 
7.  ENSG00000239188 snoRNA -1.562 0.00005 -1.235 0.01288 
8.  ENSG00000252290 snoRNA -1.241 0.02864 1.237 0.03033 
9.  hsa-miR-339 stem-loop 1.289 0.03267 1.312 0.02403 
10.  hsa-miR-1228* stem-loop -1.167 0.02415 1.160 0.02888 
11.  hsa-miR-4309* stem-loop 1.448 0.00026 -1.172 0.04897 
12.  hsa-miR-4692 stem-loop -1.298 0.03144 1.284 0.03749 
13.  hsa-miR-548au stem-loop -1.234 0.02995 -1.292 0.01113 
14.  hsa-miR-548a-3p* miRNA -2.388 0.02041 -2.564 0.01362 
15.  hsa-miR-645* miRNA 1.194 0.03779 1.204 0.03067 
16.  hsa-miR-1254* miRNA -1.671 0.02557 -1.657 0.02756 
17.  hsa-miR-2682-5p miRNA 1.189 0.03746 1.316 0.00298 
18.  hsa-miR-3618* miRNA -1.183 0.03511 -1.194 0.02762 
19.  hsa-miR-8083 miRNA -1.270 0.03868 -1.287 0.03050 
* miRNAs with available predicted targets in the TargetScanHuman 6.2 
database.  
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c. Cancer associated pathways of arsenite-dependent mRNA differential 
expression (targets of differentially expressed small RNAs) 
In order to learn about the potential impact of the 11 differential expressed 
miRNAs (Table 3.1), potential targets of differentially expressed miRNAS was 
sought. Only 6 of the 11 miRNAs had predicted targets listed (Fig. 3.2.E). There 
were 2450 potential targets of these 6 miRNAs listed in TargetScanHuman 6.2 
database. By intersecting the list of predicted target mRNAs (2450 mRNAs) with 
the 323 mRNAs differentially expressed at both 3 and 7 weeks of arsenite 
exposure (Fig. 3.2.D), 38 predicted target mRNAs were found differentially 
expressed in arsenic-exposed cells at both time points (p-value ≤ 0.05) (Fig. 
3.2.F). Unsupervised hierarchical clustering of the 38 mRNAs showed exposure-
dependent differential expression of 13 mRNAs with 5 increased and 8 
decreased compared to unexposed cells at both time points (Fig. 3.2.G). Time-
dependent differential expression was also observed for some of the 38 mRNAs. 
In comparison to 3 weeks, 15 mRNAs were induced and 15 were suppressed at 
7 weeks. Expression of twelve mRNAs were reversed by arsenite exposure (Fig. 
3.2.H).  
In order to gain an understanding of the potential impact of these 
differentially expressed genes, we performed pathway analysis using Metacore™ 
software to place the differentially expressed target mRNAs on pathways. The 
top ten pathways are listed in Table 3.2.  
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Table 3.2. Top 10 pathways of the differentially expressed 38 mRNAs 
at both 3 and 7 weeks that are predicted targets of miRNAs 
differentially expressed at both 3 and 7 weeks. 
# Pathway FDR 
1.  Development WNT signaling pathway. 
Part 1. Degradation of beta-catenin in the absence 
WNT signaling 
1.231E-02 
2.  Action of GSK3 beta in bipolar disorder 1.231E-02 
3.  Cytoskeleton remodeling TGF, WNT and cytoskeletal 
remodeling 
1.231E-02 
4.  Signal transduction PTEN pathway 2.498E-02 
5.  Immune response NFAT in immune response 2.498E-02 
6.  Development WNT signaling pathway. Part 2 2.50E-02 
7.  PGE2 pathways in cancer 2.50E-02 
8.  Immune response CD28 signaling 2.50E-02 
9.  Ligand-independent activation of Androgen receptor 
in Prostate Cancer 
2.92E-02 
10.  Signal transduction mTORC2 downstream signaling 2.92E-02 
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Three of these pathways, cytoskeleton remodeling (predicted to be 
induced), WNT signaling (predicted to be induced) and signal transduction PTEN 
(predicted to be suppressed), are all known to play a role in carcinogenesis, and 
have a single mRNA in common. This mRNA, TCF7L2, was induced at 3 and 7 
weeks and is a predicted target for miR-548a-3p, which is significantly 
suppressed at both 3 and 7 weeks (Table 3.1). TCF7L2 is a transcription factor 
that participates in the WNT signaling pathway (among others) and promotes c-
MYC expression (276). TCF7L2 has a known role in colon cancer (277, 278).  
These results suggest that the chronic arsenite exposure at early times 
decreases the expression of miR-548a-3p, relieving suppression of TCF7L2 
expression. The increase in TCF7L2 expression then promotes these oncogenic 
pathways (Fig. 3.3).  
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Figure 3.3. Arsenite exposure suppresses miR-548a-3p relieving 
suppression of TCF7L2 translation and enabling repression of oncogenic 
pathways. ATCF7L2, a target of miR-548a-3p, expression induction at early 
stages of arsenite exposure suggests that arsenite decreases the expression of 
miRNAs 548a-3p that leads to increasing mRNA levels of TCF7L2 which regulate 
its target genes participating in transformation and carcinogenesis processes.  
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In addition to TCF7L2, MDM2 (mouse double minute 2 homolog) also is 
among the 38 target mRNAs and also is a predicted target of miR-548a-3p (Fig. 
3.4). MDM2 is a well-established suppressor of TP53 expression (279). MDM2 
mRNA was induced at 3 and suppressed at 7 weeks by microarray hybridization. 
Suppression of miR-548a-3p would increase MDM2 levels, which then can act to 
suppress TP53 (Fig. 3.4) at 3 weeks. HMG1 (High mobility group box 1 protein), 
a target of multiple differentially expressed miRNAs (Fig. 3.4), also was among 
the differentially expressed target mRNAs at 3 and 7 weeks by microarray 
hybridization. HMG1 is a predicted target of three differentially expressed 
miRNAs: miR-410, miR-548ac and miR-3174 that were all suppressed at 3 and 7 
weeks (Fig. 3.3). HMG1 acts to suppress TP53 transcription (280).   
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Figure 3.4. miRNA and Target Genes Expression. Arsenite suppressed the 
expression miR-410, -548ac and -548a-3p. MDM2 mRNA expression levels were 
induced at 3 weeks of arsenite exposure which might lead to the induction of 
MDM2 protein levels. HMG1 mRNA expression levels were induced at 3 and 7 
weeks of arsenite exposure which might lead to the induction in HMG1 protein 
levels. Arsenite suppression of miR-410 and -548ac might induce MDM2 and 
HMG1 at 3 weeks leading to the decrease in the levels of P53 and P73. P53 and 
P73 increase in autophagy which is important for tumor cells as an adaptive 
stress response and decrease in chromosomal stability and apoptosis. 
 
 
  59 
HMG1, MDM2 and TP53 protein levels were examined at 7 weeks (Fig. 
3.5). The levels of HMG1 were induced, yet the induction was not statistically 
significant. Total TP53 and phosphorylated TP53 (TP53-S15P) were induced. In 
contrast, acetylated TP53 (TP53-K382Ac) was suppressed with arsenite 
exposure. MDM2 is an oncoprotein that is has multiple isoforms and few of which 
can bind TP53 (281, 282). Several MDM2 isoforms (multiple bands) were 
detected in exposed and unexposed cells (Fig. 3.5). Although levels of MDM2 
isoforms increased in arsenite-exposed cells, only the increase of MDM2-A (~60 
kDa) was statistically significant. 
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Figure 3.5. Arsenite exposure effects on MDM2, TP53 and HMG1 
expression. After 7 weeks chronic exposure A) Western blot and quantitation 
showing increased expression of MDM2 isoform A (MDM2-A, 60 kDa), but not 
MDM2-FL. B) Western blot and quantitation showing no change in HMG1. C) 
Western blot and quantitation showing both TP53 and phosphorylated TP53 at 
serine 15 were induced with arsenic exposure. D) Western blot and quantitation 
showing TP53 hypoacetylated at lysine 382 in arsenite exposed cells. Proteins 
levels were normalized to β-actin levels and means ± SD are plotted. Student T-
Test was used for statistical analyses. *p-value ≤ 0.05.
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Discussion 
The mechanism of arsenic-induced skin cancer is not well understood, but 
several studies indicate that mutation is not the driving force as it is for sunlight-
induced skin cancers (256, 283, 284). Different mechanisms of induction and 
progression of arsenic-induced carcinogenesis are proposed including miRNA 
expression dysregulation (256). The current chapter focuses on early changes in 
gene expression linked to arsenic-induced changes in mRNA and small RNA 
expression in the HaCaT cell chronic arsenic exposure model using Affymetrix 
hybridization microarrays. The results showed that arsenite exposure changes 
the expression pattern of small RNAs, including miRNAs, after 3 and 7 weeks 
exposure to 100 nM arsenite (Fig. 3.2).  
The results identified three of the six miRNAs with predicted targets that 
were differentially expressed after 3 and 7 weeks (miR-1228, miR-1254, miR-
645). These miRNAs were associated with cancer in previous studies (285-287). 
MiR-1228 (suppressed at 3 weeks, induced at 7 weeks) was reported to be 
induced in breast cancer tissues and cell lines and regulates the levels of mRNA 
and protein of SCAI (suppressor of cancer cell invasion) (286). MiR-1254 
(suppressed at 3 and 7 weeks) was reported to be induced in the sera of non-
small cell lung cancer patients (285). MiR-645 (induced at 3 and 7 weeks) was 
induced in head and neck squamous cell carcinoma and its induction was found 
to promote cell invasion and metastasis (287).  
The results also showed that arsenite dysregulated (mostly suppressed) 
several snoRNAs. SnoRNAs are 60–300 nucleotide small RNAs that are 
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concentrated in the nucleolus (288). SnoRNAs are involved in guiding premature 
ribosomal and other spliceosomal RNAs for nucleoside post-transcriptional 
modifications, crucial for accurate ribosomes (288).  SnoRNAs have two main 
classes: C/D box and H/ACA box snoRNAs, both reported to be dysregulated in 
several diseases including cancer (288, 289). These results suggest that 
dysregulation of snoRNAs may play a role in arsenic-induced carcinogenesis.  
Arsenite exposure also induced dramatic changes in differential mRNA 
expression at 3 weeks (1197 mRNAs) and 7 weeks (4840 mRNAs) (Fig. 3.2). 
This chapter focused on the 38 mRNAs differentially expressed at both time 
points that also were predicted targets of miRNAs differentially expressed at both 
time points to gain insight on plausible mechanisms by which the changes in 
miRNA expression would contribute to carcinogenesis.  
Several carcinogenesis-associated pathways such as cytoskeleton 
remodeling, WNT signaling, and signal transduction PTEN pathways were 
populated by these 38 differentially expressed target mRNAs. These results 
support the hypothesis that the differential expression of miRNAs at early stages 
of arsenite exposure is contributing to the process of transformation to a 
cancerous phenotype. A mutually differentially expressed mRNA in these 
pathways was TCF7L2 (Fig. 7). TCF7L2 is the most studied member of the 
mammalian TCF/LEF family of nuclear factors. TCF7L2 polymorphisms have 
been associated with type-2 diabetes susceptibility in several studies (290-292) 
and dysregulation of TCF7L2 may be related to the association of arsenic 
exposure and diabetes (293). The WNT signaling pathway is one of the main 
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signaling mechanisms during embryogenesis and cancer development (290-
292). The β-catenin/TCF (including TCF7L2) complex is the key effector in the 
WNT pathway, which leads to the activation of downstream targets and 
increased cell differentiation, proliferation, migration and insulin sensitivity (290-
292). Both β-catenin and TCF7L2 were induced at 7 weeks (1.41- and 1.13-fold, 
respectively). However, only TCF7L2 was induced at 3 weeks, suggesting that 
there is a progression in the gene expression changes with continued arsenite 
exposure.  
E- cadherin is a calcium-dependent cell-cell adhesion protein and a key 
gene in the epithelial-to-mesenchymal transition (EMT, which is WNT signaling-
related) (290-292).  Low E-cadherin expression is associated with induction of 
EMT in cervical squamous cell carcinoma and breast cancer (294, 295). E-
cadherin mRNA expression was suppressed at 7 weeks of arsenite exposure 
(1.46-fold). Enhanced cell migration is an indicator of EMT. However, the 
migration capability of unexposed and arsenite exposed cells at 3 weeks did not 
differ (shown in chapter 5 in Fig. 5.1). These results suggest that at these early 
times of exposure, the changes in the mRNA levels of extracellular matrix 
components are not yet reflected in cellular phenotype. As for the progression 
observed with changes in mRNA expression, full development of the EMT 
phenotype many require longer exposures.  
Of the 38 mRNAs differentially expressed after 3 and 7 weeks chronic 
exposure, MDM2 mRNA was induced at 3 weeks and suppressed after 7 weeks. 
MDM2 is a potential target of several miRNAs including miR-548a-3p that was 
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suppressed in early exposure. Moreover, HMG1 mRNA was induced in early 
exposure. HMG1 is a potential target for 3 miRNAs found suppressed in early 
exposure. Both MDM2 and HMG1 can regulate TP53 expression. The induction 
in MDM2 and HMG1 expression was investigated along with MDM2 and HMG1 
effect on TP53 protein levels.  
MDM2 is a TP53-specific E3 ubiquitin ligase and the main cellular 
antagonist of TP53 (296). MDM2 has multiple isoforms, a few of which can bind 
TP53, such as MDM2-FL (281, 282). The protein levels of some MDM2 isoforms 
were changed at 7 weeks. MDM2 spliced variants expression has been observed 
in several types of cancer including bladder cancer (297), cancerous and normal 
breast tissues (298, 299), soft tissue sarcomas (300, 301), and giant cell tumors 
of the bone (302). MDM2-FL is the MDM2 isoform responsible for the 
ubiquitination of p53 for proteasomal degradation because it contains TP53 
binding domain (281, 282, 303). MDM2-FL levels did not change significantly 
(Fig. 3.5A). MDM2-A is a less common isoform of MDM2 and along with MDM2-
B it binds to MDM2-FL and the interaction was found to prevent MDM2-mediated 
TP53 degradation (304). MDM2- A (~60 kDa) was expressed in higher levels with 
arsenite exposure. Therefore, the induction in MDM2-A expression may be 
preventing MDM-FL from regulating TP53, resulting in the higher TP53 levels 
observed. 
HMG1 is a well-known active chromatin-associated protein implicated in 
autophagy (305). HMG proteins can modulate transcriptional activity of several 
receptors and protein complexes such as steroid hormone receptors, NF-KB, 
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TP53 and TP73 transcriptional complexes, and homeobox containing proteins 
(TBP), and also facilitates V(D)J recombination (306). HMG1 is overexpressed in 
several tumors and tumor cells including chemically-induced SCC in mice, 
human bladder cancer tissue and melanoma cells (64, 306-308). Although HMG1 
mRNA levels were dysregulated, HMG1 protein levels were variable and did not 
significantly change after 7 weeks chronic arsenic exposure (Fig. 3.5). 
In sunlight-induced skin cancer, unrepaired DNA damage (UV 
photoproducts) leads to multiple mutations, especially in the TP53. UV signature 
mutations in TP53 appear several all sunlight-induced SCC (10, 309) but not in 
arsenic-induced skin cancer (283, 284). Moreover, preliminary studies found no 
mutations in TP53 when sequenced exons 5-9 in FFPE samples of arsenic-
induced SCC, BCC or hyperkeratoses (J. C. States, personal communication). 
Thus, TP53 mutations are rare in arsenic-induced skin cancer. Because 
dominant-negative TP53 mutations can result in stabilized TP53, it was thought 
that TP53 mutations were present in arsenic-induced skin cancers due to the 
overexpression of TP53 in keratinocytes exposed to arsenic (310). However, 
later studies showed that arsenic-induced skin lesions and carcinomas lack TP53 
mutations and the gene is functional (283, 284). Investigators have also reported 
that arsenite exposure (0.1-5 μM) in several cell lines can induce TP53 (311, 
312). Hybridization microarray data showed that TP53 mRNA was suppressed in 
early chronic exposure. However, TP53 protein levels were induced along with 
TP53 phosphorylated at Ser-15 (Fig. 3.5). Phosphorylation of TP53 at Ser-15 
prevents MDM2 from binding leading to the stabilization of TP53 (313). TP53 at 
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Ser-15 phosphorylation also activates ATM-mediated DNA-damage response 
(313). However, DNA repair genes that are known P53 targets such as DDB2, 
XPC and DNA polymerase beta were not induced when examined by RNA-seq 
(RNA_seq experiments are discussed in chapter 5). Therefore, the DNA damage 
response is being dysregulation. Moreover, the elevated levels of MDM2A (Fig. 
3.5) also likely contribute to TP53 stabilization by preventing its ubiquitinylation 
(314). At 100 nM sodium arsenite exposure, the HaCaT cells do not have high 
apoptosis indexes. Thus, the induced TP53 might not be active in these cells 
(315). Acetylation is required for TP53 transcriptional activity. Therefore, 
acetylation at the key acetylation site Lys-382 (316) was quantified and found 
lower in exposed cells (Fig. 3.5). TP53 hypoacetylation suggests that TP53 is 
transcriptionally inactive. These results suggest that inactive TP53 may 
contribute to increased clastogenesis that arsenic is known to cause contributing 
to genomic instability (317).  
Along with the changes that were observed in the miRNA and mRNA 
expression in HaCaT cells at early time points, a recognized change in the 
growth of these cells was observed (Fig. 3.1). The calculated cumulative 
population doublings showed that growth rates were slower at early times in 
arsenite exposed cells. When the cells reached 19 weeks, the growth curves 
shifted and the arsenite exposed cells grew faster from 19 weeks till 32 weeks 
(Fig. 5). Others (39) have observed that HaCaT cells chronically exposed to 100 
nM NaAsO2 grow more slowly than parallel cultures of unexposed cells until 
approximately 19-20 weeks of exposure when the transformation starts (66). The 
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results suggest that 19 weeks is another important time point to study arsenic-
induced transformation in which the behavior of the cells is clearly changing.  
Taken together the results described in this chapter suggest that the early 
changes in miRNA profiles and their target genes in human keratinocytes 
contribute to arsenic-induced carcinogenesis. Therefore, studies evaluating gene 
expression at longer exposure times will be needed to reveal the role miRNA and 
mRNA expression changes play in arsenic induced carcinogenesis. Testing the 
hypotheses by looking at protein levels and posttranslational modifications 
indicate that TP53 was induced, but inactive, stressing the importance of testing 







CELL CYCLE PATHWAY DYSREGULATION IN HUMAN KERATINOCYTES AT 
EARLY STAGES OF CHRONIC EXPOSURE TO LOW ARSENITE 
Introduction 
The mechanism(s) of arsenic-induced carcinogenesis is still controversial 
(255, 256). Arsenic-induced genomic instability is suggested to play a major role 
in driving carcinogenesis. Arsenic is known to disrupt genomic integrity via cell 
cycle pathway dysregulation, DNA repair inhibition, epigenetic modifications, 
chromosomal abnormalities, disabled apoptosis and telomere dysfunction (318). 
Epigenetic factors modified by arsenic exposure include histone acetylation and 
methylation, DNA methylation, and miRNA expression (25, 26, 257-259, 318, 
319).  
In chapter 3, differentially expressed miRNAs and mRNAs in the HaCaT 
cells after 3 and 7 weeks of arsenic exposure were identified using hybridization 
microarrays. After 7 weeks exposure, more mRNAs were differently expressed. 
Furthermore, differentially expressed target mRNAs of differentially expressed 
miRNAs at both early time points were also identified. These mRNAs were found 
to be involved in several carcinogenesis related pathways suggesting that 




The various stages starting from the early stages of the transformation 
process in this HaCaT cell model have not been studied. The mRNA expression 
profiles are an important tool in identification of dysregulated pathways and 
alterations in cellular mechanisms. Therefore, in the current chapter, pathways of 
the differently expressed mRNAs after 7 weeks exposure are identified and 
investigated.   
The pathway analyses reveal differential expression of a wide array of 
genes responsible for cell cycle regulation. Arsenic has been reported to disrupt 
and delay cell cycle in its several phases, G1, S, G2/M and G2, in several cell 
lines (320-324). The gene expression data, supported by cell cycle flow 
cytometry assay analysis, suggested a delay in entering G1 phase. Therefore, 
the data suggest that cell cycle dysregulation plays a role in early events leading 
to arsenic-induced transformation. 
 
 70 
Materials and Methods 
a. Cell Culture and RNA Isolation 
We adopted the HaCaT model of Pi et al. (2008) for these studies. 
Multiple cultures of cells (4 with and 4 without 100 nM NaAsO2) were maintained 
separately for 3 weeks as detailed in chapter 3 materials and methods. Total 
RNA was purified and RNA quality was determined as detailed in chapter 3 
materials and methods. 
b. Microarray Analysis 
Expression profiles of mRNA were obtained using GeneChip® 
PrimeView™ Human Gene Expression Affymetrix arrays as described in chapter 
3. Scheme outlined in Figure 4.1 was followed in data analysis. The list of 
differentially expressed mRNAs at 7 weeks was narrowed down to 644 by 
adapting |1.5| as a fold change cutoff. 
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Figure 4.1. HaCaT cells were exposed to 0 or 100 nM NaAsO2 for 7 weeks. 
RNA was purified and expression determined on Affymetrix microarrays and 





c. Flow cytometry cell cycle assay 
HaCaT cells exposed to 0 or 100 nM NaAsO2 for 7 weeks were seeded at 
density of 1 X 106 cells per 55 cm2 cell culture dish with arsenite exposure 
maintained. After 48 h, the cells were harvested by trypsinization, collected by 
centrifugation at 1000 χg for 1 min, washed twice with PBS, and then fixed in 
70% ethanol for 24 h at 4ºC. The cells were then centrifuged at 1500 g for 1 min, 
suspended in PBS (400 μl), then RNaseA (10 mg/ml, 50 μl) and propidium iodide 
(2 mg/ml, 10 μl) were added followed by a 30 minute incubation in the dark at 
room temperature. Fluorescence was acquired by flow cytometry on a Becton 
Dickinson FACSCalibur™ (BD Biosciences) (325). Cell cycle distribution was 
determined using FlowJo® v10.2. Student’s T-Test was used for statistical 





a. Arsenite-dependent differential mRNA expression  
Analysis of the mRNAs data revealed that 644 mRNAs were differentially 
expressed at |1.5| fold change in HaCaT cells exposed to 100 nM NaAsO2 for 
seven weeks. More than half of the mRNAs were suppressed with arsenite 
exposure and the remainder were induced (Fig. 4.2.A).  The differentially 
expressed genes were then loaded into Metacore™ software for pathways 
analysis. The 15 pathways with FDR values ≤0.05 are listed in Table 4.1. Cell 
cycle and cell cycle regulation pathways are highly represented in this list (7 of 
15). Other pathways that were dysregulated include epithelial-to-mesenchymal 
transition (EMT), cytoskeleton remodeling, apoptosis, immune response and gap 
junction pathways. The mRNAs populating these pathways were analyzed for 
potential interactions. The interacting genes are shown in a network built by 
Metacore™ software (Fig. 4.2.B). Three E3 ubiquitin ligase complexes known to 
regulate cell cycle are present in this network (Siah1/SIP/EBI; CUL1/RBX1; 
SKP2/TRCP/FBXW) (326-328). A subnetwork of genes involved in regulating 
licensing of the DNA replication origin (CDT1; MCM4/6/7 complex; MCM2) (329) 







































































































































































































































































































































































































































Table 4.1. Pathways populated by differentially expressed mRNAs 7 
weeks. 
Pathway*  FDR 




Cell cycle Start of DNA replication in 
early S phase 
4.54E-10 13  
Cell cycle Role of SCF complex in 
cell cycle regulation 
7.44E-07 10  
Cytoskeleton remodeling 
Neurofilaments 
0.001 7  
Cell cycle Transition and termination 
of DNA replication 
0.001 7  
Immune response Antigen 
presentation by MHC class I, 
classical pathway 
0.002 9  
Cell cycle (generic schema) 0.002 6  
Immune response IL-4-induced 
regulators of cell growth, survival, 
differentiation and metabolism 
0.004 9  
Development Regulation of 
epithelial-to-mesenchymal transition 
(EMT) 
0.004 9   
Cell cycle Regulation of G1/S 
transition (part 2) 
0.004 6  
Cell cycle Regulation of G1/S 
transition (part 1) 
0.004 7  
Apoptosis and survival Endoplasmic 
reticulum stress response pathway 
0.008 8  Protein folding 
Cell cycle ESR1 regulation of G1/S 
transition 
0.014 6  
Proteolysis Putative ubiquitin 
pathway 
0.016 5  
Transcription Ligand-dependent 
activation of the ESR1/SP pathway 
0.049 5 
 cell cycle 
regulation 
Cell adhesion-Gap junctions 0.049 5  
*Pathway analysis performed by Metacore software with expression criteria 
≥|1.5| fold change, FDR ≤0.05. 
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b. Arsenite-dependent increase in G2/M compartment 
The gene expression data suggested dysregulation of cell cycle was 
occurring in arsenite exposed cells. To confirm cell cycle dysregulation, cell cycle 
analyses were performed on the four exposed and 4 unexposed cultures. The 
results indicate that arsenite-exposed cells are accumulating in the G2/M 
compartment suggesting a delay in either the G2 to M phase or M to G1 phase 
transition (Fig. 4.3). These results are consistent with the network results of 





Figure 4.3. Arsenite-exposed HaCaT cells accumulate in the G2/M 
compartment. A. Flow cytomteric analysis of cell cycle in four cultures of HaCaT 
cells after 7 weeks exposure to 0 or 100 nM NaAsO2. Cells were fixed, RNAse A 
digested and stained with propidium iodide. Data were collected by flow 
cytometry and analyzed using FloJo software. B. Fraction in each compartment 
(G1, S, G2/M) were determined and means ± SD are plotted. Student T-Test   




Arsenic is a known human carcinogen (82). Several mechanisms of 
arsenic carcinogenicity including genomic instability and chromosomal 
abnormalities have been proposed (319). Arsenic exposure has been associated 
in several studies with dysregulation of DNA methylation, cell cycle, and DNA 
repair gene expression (21, 257, 258, 330). However, there is not yet agreement 
on the mechanism(s) of arsenic transformation. Chronic low arsenic exposure 
leads to the malignant transformation of cell lines from several tissues (39, 331-
333). Transformation is likely to be driven by a series of events starting from 
early times of exposure and extending out to as much as thirty weeks exposure 
when transformation can be demonstrated to have occurred. Early events in 
transformation in these model systems have not yet been investigated. Thus, we 
have examined gene expression changes in the HaCaT model of arsenic-
induced skin carcinogenesis after seven weeks’ exposure to gain an 
understanding of the early events related to transformation.  
The population growth curves in chapter 3 and reported by others (39) 
indicate that HaCaT cells chronically exposed to 100 nM NaAsO2 grow more 
slowly than parallel cultures of unexposed cells until approximately 19 weeks 
exposure. Dysregulation of cell cycle control as suggested by the differential 
expression and pathways data presented in this chapter is consistent with these 
earlier observations on cell growth kinetics. This conclusion is further supported 
by cell cycle assay analysis on HaCaT cells after seven weeks’ exposure that 
showed accumulation of cells in the G2/M compartment (Figure 4.3). This 
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observation is consistent with the network analysis showing induction of genes 
associated with licensing replication origins (CDT1, MCM2/4/6/7, Figure 4.2.B). 
These observations are consistent with G2/M delays observed in earlier studies 
in the States laboratory (323, 334-336) and by others (337, 338).  
The E3 ubiquitin ligase complexes identified in the network analysis 
(Figure 4.2) are all zinc finger RING E3’s that regulate cell cycle transitions other 
than G2 to M or M to G1. Thus, although the genes involved in replication origin 
licensing suggest a major impact on M to G1 transition, the induction of these E3 
ubiquitin ligase genes suggests that the cells are responding to delays at other 
cell cycle transitions as well. Impact of arsenite exposure at multiple cell cycle 
transitions was demonstrated by McCollum et al in U937 cells (337), and by S 
phase lengthening in MCF7 and H1299 cells by Pozo-Molina et al. (339). 
Accumulation in the G0/G1 phase leading to reduction in the S phase also was 
observed with mouse skin fibroblast cells (m5S), mouse thymocytes and B-cell 
lymphoma A20 cells (340, 341). It was also reported that HL-60, derived from a 
patient with acute myeloid leukemia (FAB), were arrested at G1 with arsenic 
exposure (342). Furthermore, Moghaddaskho et al. 2017 showed that arsenic 
arrested MDA-MB-231 and MDA-MB-468 cells at G2/M phase (343). Clearly, 
arsenite exposure can cause cell cycle disruption in all cell cycle phases. 
However, delays in M phase are likely to contribute to genomic instability via 




A LONGITUDINAL STUDY ON SMALL RNA AND MRNA EXPRESSION 
PROFILES IN THE CHRONIC EXPOSURE HACAT MODEL 
Introduction  
The results obtained in chapters 3 and 4 showed that early times of 
chronic arsenite exposure lead to differential small RNA and mRNA expression 
with a more differentially expressed mRNAs at 7 weeks. Moreover, arsenite 
exposed cells grew slower at early times. The growth curves shifted at 19 weeks, 
and arsenite exposed cells then grew faster than unexposed cell all the way to 32 
weeks (Fig. 3.1). Others have also observed that HaCaT cells chronically 
exposed to 100 nM NaAsO2 grow slower till 19-20 weeks when transformation 
starts (66). The results suggest that 19 weeks is another important time point to 
study arsenic-induced transformation because the behavior of the cells is clearly 
changing. Further, Pi et al (2008) showed that 28 weeks of exposure of HaCaT 
cells to 100 nM sodium arsenite transformed these cells fully and resulted in an 
aggressive SCC phenotype when inoculated into nude mice (39). Therefore, 28 
weeks is a third important time point to study in the transformation path. Thus, in 
this chapter, a longitudinal study was performed to determine small RNA and 
mRNA differential expression in HaCaT cells chronically exposed to 100 nM  
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NaAsO2 at 3 time points: 7 weeks (transformation related changes), 19 
weeks (start of actual transformation) and 28 weeks (fully transformed cells). 
Next-generation sequencing (NGS) is a high-throughput sequencing tool used for 
genome sequencing and resequencing, transcriptome profiling (RNA-Seq), DNA-
protein interactions (ChIP-sequencing), and epigenome sequencing (344). NGS 
is very time and cost effective. The entire human genome can be sequenced in 
few hours with about $1000 versus 60 years with $30 million using first 
generation sequencing (Sanger sequencing) (345). RNA sequencing (RNA-seq) 
was one of the earliest forms of nucleotide sequencing for transcriptome profiling 
(1972) (346). NGS development has the greatest impact on advancing 
transcriptomes by allowing massive scale RNA analysis through cDNA 
sequencing (347). RNA-seq is a quantitative and qualitative measure of the 
transcriptome (347). RNA-seq is capable of providing expression profiles and 
mutational status along with gene fusion detection, small RNA characterization 
and alternative splicing events detection (347). In this chapter, RNA-seq was 
used to obtain both mRNA and small RNA expression profiles in the HaCaT cell 
chronic exposure model to study the effects of arsenite on the transcriptome.  
The data were further analyzed and miRNAs differentially expressed 
among all the time points were determined. Moreover, differentially expressed 
mRNAs targets of differentially expressed miRNA at each time points were 
determined. Pathway analyses were also performed for both total mRNAs and 
miRNAs target mRNAs at each of the time points. The pathway analyses show 
that most of transformation-related changes take place at 19 weeks. Several 
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carcinogenesis-related pathways are dysregulated among the different time 
points. Furthermore, only 1 miRNAs, suppressed in all three time points, is 
predicted as a novel tumor suppressor miRNA.  
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Materials and Methods 
a. Cell Culture and RNA Isolation 
The HaCaT model of Pi et al. (2008) was adopted for these studies. 
Multiple cultures of cells (4 with and 4 without 100 nM NaAsO2) were maintained 
separately for 7, 19 and 28 weeks as detailed in chapter 3 materials and 
methods. Total RNA was purified and RNA quality was determined as detailed in 
chapter 3 materials and methods. 
b. mRNA and miRNA Next-Generation Sequencing (NGS) 
1. Library Preparation, Cluster Generation and Sequencing 
Library Preparation, Cluster Generation and Sequencing of all 24 samples 
were performed in the CGeMM DNA Facility Core at the University of Louisville 
by Elizabeth Hudson. The Truseq Stranded mRNA kit was used to prepare 
mRNA libraries from 1 μg total RNA. Libraries were validated on the Agilent 2100 
Bioanalyzer and quantitated using the Illumina Library Quantification Kit, ABI 
Prism qPCR Mix from Kapa Biosystems and the ABI7900HT real-time PCR 
instrument. All samples were pooled and run simultaneously on 4 flow cells, 
using 2x150 paired end sequencing with the 500 High-output v2 (300 cycles) 
sequencing kit on the Illumina NextSeq500 instrument.   
The Truseq Small RNA kit was used to prepare miRNA libraries from 1 μg 
total RNA. Each Library was individually gel purified on a Novex TBE 6% gel and 
resuspended in 10 μL 10 mM Tris-HCl, pH 8.5. Libraries were validated and 
quantitated by running 1 μL on the Agilent Technologies 2100 Bioanalyzer DNA 
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High Sensitivity Chip. 36-cycle single sequencing reads were generated on the 
Illumina NextSeq500 instrument utilizing the 500 High output v2 (75 cycle) 
sequencing kit. 
2. Data Mapping  
Paired end RNA-Seq data were generated for each condition to which the 
cell lines were exposed. The data for each replicate were stored, trimmed, 
mapped, and quantified individually. Trimgalore, a wrapper written for the 
algorithm cutadapt (348) was used to trim, and quality filter the newly generated 
reads. The trimmed reads were mapped to the human reference genome hg19 
(NCBI build 37.1 released 2009) using the RNA-Seq mapping software TopHat 
(349) and annotated transcripts were quantified in units of FPKM using Cufflinks 
(349). The gene annotation used for the quantification was downloaded from 
ENSEMBL (version 81). This file was filtered to remove all records from the gtf 
file whose molecular biotype was annotated as either ribosomal RNA (rRNA), or 
mitochondrial tRNA (Mt_tRNA). The resultant files were used in cufflinks 
(arguments--GTF Hs_build-37.1.gtf (MT or RRNA filtered out) --compatible-hits-
norm-M Hs_build 37.1_MT_RRNA.gtf (only MT and RRNA)) and cuffdiff (GTF 
argument set to Hs_build-37.1.gtf (MT or RRNA filtered out)) to ensure no 
ribosomal RNA or mitochondrial RNA that remained after efforts to remove them 
during the library prep would not influence the derived FPKM values. Differential 
analysis was ultimately done using the cuffdiff program, which generated p-
values, as well as p-values corrected for multiple testing.  
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3. Statistical Analysis 
Data analysis was performed by comparing the log values of the 
Fragments Per Kilobase of transcript per Million mapped reads (FPKM) 
generated from the sample reads +1E-5 of exposed cells to the unexposed cells 
at 7, 19 and 28 weeks time points of exposure. The p-values for these 
comparisons were calculated by two sample T-Test with equal (p_Eq) and 
unequal variances (p_Ueq). The fold changes of the compared values were 
calculated using the equation: FC= mean (Exposed FPKM+1E-5)/mean 
(Unexposed FPKM+1E-5). All analyses were obtained using SAS System V9. 
Cary, NC: SAS Institute Inc, 2003. 
c. Determining miRNA target mRNAs and Pathway analyses 
Potential targets of differentially expressed miRNAs after 7, 19 and 28 
weeks chronic exposure (p-value ≤ 0.05) were obtained from the 
TargetScanHuman 6.2 database and compared to mRNA data obtained at the 
same three time points using Partek Genomic Suite™ software. Ingenuity® 
Pathway Analysis (IPA®) was used for all pathway analyses. 
d. Silicone Plug Assay (Cell Migration assay): 
HaCaT cells (quadruplicate unexposed and exposed cultures for 3 and 34 
weeks) were plated in a 6-well dish (550,000 cells /well; each well containing 
previously placed silicone plugs) as described in Peterson et. al. (350). Silicone 
plugs were removed after 48 h and the cells were photographed before and after 
16 h incubation in serum-free media to measure cell migration. The migration 
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area was quantified using automated_migration_assay program developed by 
Gregory J. R. States at the University of Louisville. Lines to indicate borders at 0 
and 16 h were drawn and significant differences determined by Student’s T-Test 




a. Differential miRNAs Expression  
The results showed that 59 miRNAs were differentially expressed at the 7 
weeks chronic arsenic exposure. Of the 59 differentially expressed miRNAs, 32 
were induced and 27 were suppressed. After 19 weeks chronic exposure, 124 
miRNAs were differentially expressed. Of the 124 differentially expressed 
miRNAs, 77 were induced and 47 were suppressed. After 28 weeks chronic 
exposure, 53 miRNAs were differentially expressed. Of the 53 miRNAs, 25 were 
induced and 28 were suppressed.  
Eighteen miRNAs differentially expressed in more than one of the time 
points (Table 5.1). One miRNA, miR-6733, was suppressed at all the time points 
in arsenic exposed cells. Targets of miR-6733 differentially induced in any of the 
time points were obtained. Pathway analysis of these mRNA did not show 
associations with several pathways except for 19 weeks targets. 19 weeks miR-
6733 targets were found to be involved in DNA methylation and transcriptional 
repression signaling, gap junction signaling and sumoylation pathways.  
Eight miRNAs were differentially expressed at both 7 and 19 weeks. Two 
miRNAs were suppressed at 7 and induced 28 weeks. Furthermore, 7 miRNAs 


















Suppressed at 7, 19 and 28 weeks 
hsa-mir-6733 0.024 0.058 -19751 0.024 0.058 -21501 0.037 0.075 -2 
Induced at 7 and 19 weeks 
hsa-mir-4786 0.019 0.050 3 0.049 0.057 1 0.814 0.818 -1 
hsa-mir-7974 0.027 0.044 5 0.023 0.029 2 0.535 0.539 1 
Suppressed at 7 and 19 weeks 
hsa-mir-34b 0.003 0.005 -3 0.024 0.058 -4 0.532 0.537 2 
hsa-mir-181a-1 0.038 0.076 -1 0.012 0.038 -1 0.364 0.371 -1 
hsa-mir-181a-2 0.040 0.080 -1 0.012 0.037 -1 0.330 0.337 -1 
Suppressed at 7 and induced at 19 weeks 
hsa-mir-362 0.037 0.055 -1 0.005 0.023 1 0.378 0.395 -1 
hsa-mir-7705 0.043 0.062 -2 0.001 0.011 -2 0.684 0.698 -1 
Induced at 7 and suppressed at 19 weeks 
hsa-mir-1268b 0.040 0.080 2 0.004 0.010 -2 0.230 0.239 1 
Suppressed at 7 and 28 weeks 
hsa-mir-218-1 0.047 0.088 -2 0.977 0.977 -1 0.030 0.066 -2 
hsa-mir-218-2 0.048 0.090 -2 0.968 0.969 -1 0.025 0.059 -2 
Induced at 19 and 28 weeks 
hsa-mir-99a 0.085 0.131 1 0.018 0.024 3 0.033 0.040 3 
hsa-let-7c 0.692 0.705 -1 0.018 0.023 2 0.030 0.036 2 
Induced at 19 and suppressed at 28 weeks 
hsa-mir-29b-2 0.245 0.288 -2 0.037 0.044 -1 0.002 0.004 -1 
hsa-mir-29b-1 0.253 0.295 -1 0.020 0.025 -1 0.003 0.005 -1 
hsa-mir-3651 0.386 0.392 1 0.015 0.020 -2 0.004 0.006 -1 
 Suppressed at 19 and Induced at 28 weeks 
hsa-mir-934 0.434 0.464 -1 0.011 0.016 -4 0.043 0.062 1 
hsa-mir-378c 0.435 0.465 -1 0.008 0.012 -1 0.038 0.057 1 
* P_Eq anp_UEq  
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b. Differential mRNAs Expression  
The results showed that 3654 mRNAs were differentially expressed after 7 
weeks chronic exposure (1805 induced and 1849 suppressed). After 19 weeks 
chronic exposure, 4665 mRNAs were differentially expressed (2125 induced and 
2125 suppressed). After 28 weeks chronic exposure, 2624 were differentially 
expressed (1154 induced and 1470 suppressed).  
c. Pathway Analysis of Differentially Expressed mRNAs 
Pathway analysis of the differentially expressed mRNA from the three time 
points (7, 19 and 28 weeks) was performed using Ingenuity® Pathway Analysis 
(IPA®). Several pathways were predicted to be either induced or suppressed 
based on their Z-score values (positive value= induced, negative 
value=suppressed). Pathways with Z-score ≥ |1| were selected (Table 5.2).  
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After 7 weeks chronic exposure, mRNAs in several pathways were 
induced including cell cycle, e.g. G1/S checkpoint regulation pathway, suggesting 
a delay in cell cycle. The analyses also showed that mRNAs in the basal cell 
carcinoma signaling pathway were induced. When examining the suppressed 
pathways, mRNAs populating several cytoskeleton, extracellular matrix (ECM) 
and migration signaling associated pathways, such as Integrin Signaling, RhoA 
Signaling and Actin Cytoskeleton Signaling, were suppressed. However, cellular 
migration behavior was not significantly affected by arsenic at an earlier time 
point (3 weeks) as examined by migration assay (Fig. 5.1). Similarly, mRNAs 
populating cytoskeleton, ECM and migration signaling associated pathways 
including, regulation of actin-based motility by Rho and actin cytoskeleton 
signaling were suppressed after 19 weeks chronic exposure. Furthermore, 
mRNAs in the RhoA signaling pathway were suppressed after 28 weeks chronic 
exposure. However, the migration assay of the same cells after 34 weeks chronic 














Figure 5.1: Arsenite did not affect cell migration. A. Quadruplicate HaCaT 
cultures incubated with 0 or 100 nM sodium arsenite for 7 and 34 weeks were 
photographed after 16 h incubation ± EGF in serum-free media. The migration 
area was quantified using automated_migration_assay program developed by 
Gregory J. R. States, M.S. at the University of Louisville. Lines indicate border at 




d. mRNA Targets of Differentially Expressed miRNAs 
Potential targets of differentially expressed miRNAs after 7, 19 and 28 
weeks chronic exposure were obtained and compared to mRNA data obtained at 
the same three time points using. After 7 weeks chronic exposure, 20 of 59 
differentially expressed miRNAs were found to target one mRNA or more of a list 
of 336 mRNAs that are also differently expressed at the same time point. 
Similarly, 64 of 124 differentially expressed miRNAs were found to target one 
mRNA or more of a list of 695 mRNAs that are also differently expressed at 19 
weeks. After 28 weeks chronic exposure, 28 miRNAs of 53 differentially 
expressed miRNAs were found to target one mRNA or more of a list of 
291mRNAs differently expressed at the same time point.  
e. Pathways of mRNA Targets of Differentially Expressed miRNAs  
Pathway analyses were performed using IPA® for the differentially 
expressed target mRNAs for each of the three time points obtained and 
described in the previous section. Based on the Z-score values of each pathway, 
pathways with Z-score ≥ |1| were selected (Table 5.3). After 7 weeks chronic 
exposure, induced mRNAs populated several pathways including cell cycle 
pathways, G1/S Checkpoint Regulation, along with cancer related pathways, 
glioblastoma multiforme signaling and mTOR signaling. However, the glioma 
signaling, ERK/MAPK signaling and melanocyte development and pigmentation 
signaling pathways were predicted to be suppressed. Suppression in melanocyte 
development and pigmentation signaling was also predicted. 
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After 19 weeks chronic exposure, several more pathways were predicted 
to be induced and suppressed. Larger number of cancer and diabetes-related 
pathways were predicted to be induced. Notably, TP53 and PTEN signaling 
pathways were suppressed. After 28 weeks chronic exposure, fewer pathways 
were predicted to be induced and suppressed. Cytoskeleton and ECM 
remolding-related pathways were also predicted to be induced.
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Table 5.3. Pathway analysis of differentially expressed mRNAs targets of 
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CD28 Signaling in T 
Helper Cells 
0.813 0.0551 1.134 
GAB1,BCL10,IL2,ARPC5,
PDPK1,IRS2,PPP3CA 











ErbB2-ErbB3 Signaling 1.06 0.0735 1 
GAB1,PDPK1,ERBB3,IR
S2,ELK1 
PAK Signaling 0.869 0.06 1 
PAK4,GAB1,PAK6,PAK2,
IRS2,PDGFRB 




Type I Diabetes Mellitus 
Signaling 
0.773 0.0561 1 
MAP3K14,IL2,SOCS6,TN
FRSF1B,FAS,IRF1 
Telomerase Signaling 0.76 0.0556 1 
GAB1,HDAC8,IL2,HDAC7
,PDPK1,IRS2 
Apoptosis Signaling 0.705 0.0562 1 
MAP3K14,CASP2,TNFRS
F1B,CASP7,FAS 
HGF Signaling 0.687 0.0526 1 
MAP3K14,GAB1,HGF,IR
S2,ELK1,RAP1A 
Non-Small Cell Lung 
Cancer Signaling 
0.554 0.0519 1 STK4,GAB1,PDPK1,IRS2 




Signaling In Dorsal Horn 
Neurons 
0.439 0.0439 1 
GAB1,PRKACA,KCNQ3,I
RS2,ELK1 
Synaptic Long Term 
Potentiation 
0.408 0.0424 1 
PPP1R1A,ADCY1,PRKA
CA,RAP1A,PPP3CA 
p38 MAPK Signaling 0.4 0.042 1 
SRF,PLA2G3,ELK1,TNF
RSF1B,FAS 
Suppressed pathway         
Cholecystokinin/Gastrin-
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0.855 0.0594 -2 
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A4,MAPK7,ELK1 




Regulation of Actin- 1.1 0.0698 -1 PAK4,PAK6,RHOC,PAK2
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based Motility by Rho ,ARPC5,PIP4K2C 
PTEN Signaling 0.4 0.042 -1 
FLT1,TGFBR3,PDPK1,IN
PP5K,PDGFRB 




   
  
Induced pathway         
ERK/MAPK Signaling 1.18 0.0303 1.633 
PLA2G6,PAK1,ITGA3,TL
N2,PLCG1,DUSP4 





1.01 0.0271 1 
PAK1,ITGA3,TLN2,FGF1
8,WASF1,APC 
Integrin Signaling 0.443 0.0189 1 
PAK1,ITGA3,TLN2,PLCG
1 
Suppressed pathway         
Macropinocytosis 
Signaling 
1.54 0.0494 -1 MET,PAK1,CSF1,PLCG1 






The mechanisms of arsenic-induced carcinogenesis are not yet clear. 
Several mechanisms, including epigenetic alterations are proposed. MiRNAs are 
part of the epigenome and play an important role in gene regulation and cellular 
development (351). Master developmental pathways are altered in cancer. 
Therefore, both small RNA and mRNA expression are very important in 
mechanistic studies of cancer in general and chemically-induced cancers in 
particular. RNA-seq is a NGS tool that gives a quantitative and qualitative 
measure of the transcriptome (347). In this chapter, RNA-seq was used to obtain 
mRNA and small RNA expression profiles in a longitudinal study of the HaCaT 
cell chronic exposure model. 
The data showed that numerous miRNAs and mRNAs were differentially 
expressed among all the time points, noticeably after 19 weeks chronic 
exposure. Only one miRNAs miR-6733, was suppressed at the three time points. 
MiR-6733 suppression was the highest at 7 and 19 weeks and the lowest at 28 
weeks. MiR-6733 has not yet been mentioned or discussed in the literature to be 
dysregulated with any disease except with bladder cancer (352). Thus, the 
results suggest that miR-6733 might be a novel tumor suppressor that plays a 
role at early stages of transformation. Furthermore, the pathway analysis of miR-
6733 targets, induced at 19 weeks, predicted their involvement in DNA 
methylation and transcriptional repression signaling, gap junction signaling and 
sumoylation pathways. Moreover, let-7c and miR-99a were suppressed at 19 and 
induced 28 weeks indicating that these miRNAs are associates with the 
 
 110 
transformed phenotype. MiR-29b-2, miR-29b-1 and miR-3651 were induced at 
19 weeks and suppressed at 28 weeks and vice versa for miR-934 and miR-378c 
indicating that the changes in expression for some miRNA take opposite direction 
once the cells are fully transformed.   
Pathway analyses were also performed for both total mRNAs and miRNA 
target mRNAs at each of the time points. The analyses showed most of the 
transformation and carcinogenesis-related dysregulated pathways were 
predicted at 19 weeks time point. Several pathways were predicted to be induced 
including cell cycle: G1/S checkpoint regulation pathway suggesting a delay in 
cell cycle after 7 weeks chronic exposure. The suggested cell cycle dysregulation 
supports the results obtained and discussed at the same time point using the 
hybridization microarrays in chapter 4. Similarity, when examining the 
suppressed pathways, several cytoskeleton, ECM and migration signaling 
associated pathways were suggested to be suppressed after 7, 19 and 28 weeks 
chronic exposure. However, the cellular migration behavior was not significantly 
affected by arsenic exposure as determined by migration assay at early and later 
exposures (Fig. 5.1). Interestingly, the cells at a later stage, either exposed or 
unexposed, grew or migrated faster than the same cells at a very early stage of 
exposure (Fig. 5.1). 
Over all, most transformation related changes in pathways signaling 
direction and miRNA and gene expression and at 19 weeks are at their peak. 
Notable changes in pathways signaling direction and miRNA and gene 
expression were at 7 weeks and peaked at 19 weeks of chronic arsenite 
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exposure. These arsenite associated changes suggest that the cells 
transformation process takes place gradually till reaching a critical point, 19 
weeks, when the changes peak allowing the cells start transforming. Further 
mechanistic investigations on the unique changes that take place at 19 weeks 





MIRNA EXPRESSION PROFILES COMPARISIONS ACROSS THREE 
DIFFERENT TECHNIQUES  
Introduction  
In chapters 2 through 5, three different techniques were used to measure 
miRNA expression profiles in skin lesions and a cell line model. The first 
technique was TaqMan® Array Human MiRNA A Card v2.0 polymerase chain 
reaction (RT-qPCR) array cards, Life Technologies). The array measures the 
expression of 384 targets; 377 miRNAs and 7 controls. Card A focuses on more 
highly characterized miRNAs. TaqMan® Array cards required only minute RNA 
sample amounts. Low yields of RNA obtained from the set of FFPE skin lesions 
(discussed in chapter 2) were used to measure miRNA expression profiles using 
the TaqMan® Array Card A. MiRNA expression profiles obtained from skin 
lesions were also compared to the miRNA expression profiles of HaCaT cells 
chronically exposed to arsenite for 3 weeks obtained as well by TaqMan® Array. 
However, comparisons showed weak correlations between the profiles.  
MiRNAs play an important role in gene regulation and cellular 
development (351). Therefore, measuring the expression profiles of small RNA 
and their target mRNAs are important to study mechanisms of altered 
developmental pathways by chemically-induced cancers. Affymetrix arrays 
 
 113 
(hybridization microarrays) were used to measure both mRNA and small RNA 
expression profiles of HaCaT cells after 3 and 7 weeks chronic exposure to 
arsenite. Affymetrix arrays cover a very number of mRNA and small RNA and 
they are both time and cost effective.  
The HaCaT cells chronic arsenite exposure model was reported by Pi et 
al. as an SCC model (39). However, the model has not been evaluated. 
Furthermore, the various stages starting from the early stages of the 
transformation process in the model have not been studied yet. Therefore, one of 
the goals of this chapter is to evaluate if the HaCaT cell model is a biologically 
relevant model to study arsenic induced SCC. Therefore, a high-throughput 
sequencing tool (RNA-Seq) was used to measure mRNA and small RNA 
expression profiles at three times in HaCaT cells chronically exposed to arsenite. 
RNA-Seq is time and cost effective and provides more data than hybridization 
microarrays including expression profiles, mutational status, gene fusion 
detection, small RNA characterization and alternative splicing events detection 
(347).  
The miRNA expression profiles obtained by the 3 techniques and 
comparisons revealed many similarities, but also some differences that are 
discussed in the current chapter. 
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Materials and Methods 
a. MiRNA Profiles at 3 weeks chronic exposure by RT-qPCR Array Cards 
Profiling miRNA expression for HaCaT cells exposed to arsenite for 3 
weeks (detailed in chapter 2 and 3 materials and methods) was performed using 
the TaqMan® Array Human MiRNA A Card v2.0  (RT-qPCR) array cards, Life 
Technologies) and the data were collected at 0.1 threshold value. Statistical 
analyses were performed by comparing the ΔCt values of the arsenic unexposed 
cells to those of exposed cells using two-sample T-Test by SAS System V9. 
Cary, NC: SAS Institute Inc, 2003. 
b. Arsenic unexposed/exposed HaCaT cells (3 weeks) vs. skin lesion 
The ΔCt values were calculated using the means of Ct values of the 
arsenic exposed cell or skin lesions (HK, BCC, SCC) in comparison to 
unexposed cells and normalizing them to the Ct values of the reference RNA U6. 
Statistical analyses were performed by using two-sample T-Test by SAS System 
V9. Cary, NC: SAS Institute Inc, 2003. Then the differentially expressed miRNAs 
obtained from the comparing unexposed cells to skin lesions (HK, BCC and SCC 
vs. -As) were compared to the differentially expressed mRNAs obtained from 
unexposed and exposed cells at 3 weeks. 
c. Comparison between the 3 weeks small RNAs expression profiles obtained by 
RT-qPCR array cards and hybridization microarrays  
The significant differentially expressed miRNAs from HaCaT cells 
chronically exposed to arsenite for 3 weeks from the data obtained from both the 
 
 115 
TaqMan® Array Human MiRNA A Card v2.0 (RT-qPCR array cards) and 
hybridization microarrays (Affymetrix microarrays) detailed in chapter 3 were 
compared.  
d. Small RNAs Expression Profiles at 7 weeks Obtained by Hybridization 
Microarray vs. Next-Generation Sequencing (NGS) 
The significant differentially expressed small RNAs from HaCaT cells 
chronically exposed to arsenite for 7 weeks from the data obtained from both the 
hybridization microarrays (Affymetrix microarrays) detailed in chapter 3 and Next-
Generation Sequencing (NGS) detailed in chapter 5 were compared.  
e. Comparison between the small RNAs expression profiles obtained by 
hybridization microarray and Next-Generation Sequencing (NGS) and skin lesion 
MiRNA expression profiles of multiple cultures of HaCaT cells (4 with and 
4 without 100 nM NaAsO2) after 7, 19 and 28 weeks chronic exposure as 
detailed in chapter 5 materials and methods were compared to the MiRNAs 




a. MiRNA Expression Profiles in Arsenic Unexposed/Exposed HaCaT Cells at 3 
Weeks of Exposure. 
Eight miRNAs were differentially expressed in exposed HaCaT cells for 3 
weeks compared to unexposed cells (Table 6.1). miRNAs miR-193a-5p, miR-
892a and miR-570 were induced and miR-296-3p, miR-501, miR-412, miR-509-
5p and miR-616 were suppressed.  
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Table 6.1. Differentially expressed miRNAs at 3 weeks of chronically 
arsenic- exposed/unexposed HaCaT cells using RT-qPCR array 
cards  
microRNAs p-value  Fold Change 
Induced 
hsa-miR-193a-5p 0.015 463 
hsa-miR-892a 0.007 69 
hsa-miR-570 0.017 19  
Suppressed 
hsa-miR-296-3p 0.024 3 
hsa-miR-501 0.008 6 
hsa-miR-412 0.043 6 
hsa-miR-509-5p 0.045 27 
hsa-miR-616 0.036 86 
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b. Comparison Between Differential miRNA Expression Profiles Obtained by RT-
qPCR Array Cards of HaCaT Cells Exposed vs Unexposed to Arsenic for 3 
Weeks to Differential miRNA Expression of Skin Lesions vs. Unexposed Cells  
The miRNA profiles obtained using RT-qPCR array cards of arsenic 
unexposed HaCaT cells for 3 weeks were compared to those obtained similarly 
from each of the skin lesions (premalignant (HK) and malignant (BCC and SCC)).  
Several miRNAs were differentially expressed. Sixty-eight miRNAs were 
differentially expressed compared to HK, 27 were induced and 42 were 
suppressed. Forty-three miRNAs were differentially expressed compared to 
BCC, 15 were induced and 28 were suppressed. Forty-three miRNAs were 
differentially expressed compared to SCC, 31 were induced and 12 were 
suppressed. Fifty-three miRNAs were mutually differentially expressed among at 
least 2 of the 3 comparisons. 
We also compared the differentially expressed miRNAs obtained from 3 
weeks in arsenic exposed cells vs. unexposed cells to those of skin lesions vs. 
unexposed cells. Only two miRNAs were differentially expressed, miR193a-5p 
and miR-296-3p (Table 6.2). MiR193a-5p was induced in all comparisons, +As 








































































































































































































































































































































































c. Comparison 3 weeks small RNAs expression profiles obtained by both RT-
qPCR array cards and hybridization microarray 
Only 2 miRNAs (miR-296-3p and miR-501) were differentially expressed 
in both data sets (Table 6.3). However, these 2 miRNAs were induced in RT-
qPCR array cards and suppressed in hybridization microarrays.  
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Table 6.3. Differentially expressed miRNAs at 3 weeks of chronically 
arsenic-exposed HaCaT cells in both hybridization microarrays and RT-











hsa-miR-296-3p 0.039 2 0.024 -3 
hsa-miR-501 0.034 1 0.008 -6 
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d. Comparison 7 weeks small RNAs expression profiles obtained by both 
hybridization microarray and Next-Generation Sequencing (NGS) 
Only 9 miRNAs were differentially expressed in both hybridization 
microarray and NGS after 7 weeks chronic exposure in both techniques used 
(Table 6.4). Three miRNAs (miR-222, miR-4461, miR-744) were induced and two 
(miR-6726, miR-3614) were suppressed in both data sets. Further, two miRNAs 
(miR-3158-2, miR-3934) were suppressed in hybridization microarrays and 
induced in NGS and two miRNAs (miR-4738, miR-5580) were induced using 




Table 6.4. Differentially expressed miRNAs at 7 weeks of chronically 
arsenic-exposed HaCaT cells in both hybridization microarrays and Next-












hsa-miR-4461 0.021 4 0.021 0.026 3 
hsa-miR-744 0.010 1 0.014 0.019 2 
hsa-mir-222 0.013 1 0.011 0.015 1 
hsa-miR-4738 0.039 1 0.025 0.058 -25501 
hsa-miR-5580 0.018 1 0.000 0.000 -19501 
hsa-miR-6726 0.027 -1 0.031 0.067 -3 
hsa-miR-3614 0.001 -2 0.001 0.003 -2 
hsa-mir-3934 0.010 -1 0.020 0.035 2 
hsa-mir-3158-2 0.045 -1 0.016 0.021 2 
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e. MiRNAs Differentially Expressed in both Arsenic-Exposed HaCaT Cells and 
Arsenic-Induced Skin Lesions 
The miRNAs expression profiles of chronically arsenic-exposed HaCaT 
cells (7, 19 and 28 weeks time points) were compared with those obtained from 
skin lesions (HK, BCC and SCC) from individuals exposed to high levels of 
arsenic in their drinking water (Chapter2). Three miRNAs (miR-362, miR-381 and 
miR-452) were differentially expressed in cells and skin lesions (Table 6.5). MiR-
362 was suppressed at 7 weeks and induced at 19 weeks of HaCaT cells 
exposure. MiR-362 was also induced in SCC compared to BCC lesions, but not 
to HK. MiR-381 and miR-452 were induced at 28 and 19 weeks in HaCaT cells, 
respectively, and suppressed in BCC lesions compared to both HK and SCC 
lesions. The comparisons confirm the HaCaT chronic model as a SCC model. 


































































































































































































































































































































































































Few miRNAs (eight) were differentially expressed after 3 weeks arsenic 
exposure. Upregulation of miR193a-5p was detected in comparisons between 
arsenic exposed cells vs. unexposed cells (3 weeks) and skin lesions vs. 
unexposed cells using RT-qPCR arrays. MiR193a-5p was associated with 
several cancers including bladder cancer and malignant pleural mesothelioma 
(353, 354). MiR-296-3p was suppressed in arsenite-exposed cells compared to 
unexposed cells. However, it was induced in SCC lesions compared to 
unexposed cells. miR-296-3p was reported to be associated with several cancers 
including prostate cancer and glioblastoma (355, 356).  
Comparing 3 weeks miRNA expression profiles obtained by RT-qPCR to 
those obtained by hybridization microarrays identified only 2 miRNAs in common. 
The comparison between 7 weeks miRNA expression profiles obtained by both 
hybridization microarray (312 differentially expressed small RNAs) and RNA-seq 
(59 differentially expressed small RNAs) showed lack of reproducibility. Of the 
miRNAs that were differentially expressed, only 9 and only 5 were in the same 
direction of expression. A validation in the States lab and reported by other 
scientists to Affymetrix, Inc. by TaqMan® MicroRNA individual assays of some 
miRNAs that showed differential expression by hybridization microarrays for the 
same set of samples could not be replicated. Therefore, the larger number of 
differentially expressed miRNAs identified in hybridization microarray compared 
to RNA-seq suggests a higher false positive rate. It has been also reported that 
RNA-Seq data correlate better with microarrays for genes expressed at medium 
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levels, but not for high or low (357). Others reported validation of results from 
RNA-seq and microarrays showed the most errors with microarrays (358). 
When comparing the miRNA expression profiles between chronically 
arsenic-exposed HaCaT cells and arsenic-induced skin lesions showed (Chapter 
2) that miR-362 was suppressed at 7 weeks and induced at 19 weeks in HaCaT 
cells by RNA-seq and was induced in SCC compared to BCC lesions (by RT-
qPCR arrays). MiR-362 was reported to be induced in chronic myeloid leukemia 
(236) and in metastatic cancers such hepatocellular carcinoma (238) and gastric 
cancer (239). The results suggest that miR-362 is associated with a malignant 
and invasive phenotype because it was induced in both SCC and HaCaT cells 
exposed to arsenic for 19 weeks, the time that transformation starts to occur. 
Thus, this result supports the hypothesis that HaCaT cells chronically exposed to 
arsenic are a model of arsenic-induced SCC.  
MiR-381 was induced in HaCaT cells exposed to arsenic for 28 weeks and 
mir-452 was induced after 19 weeks exposure. The two miRNAs were 
expression in HK and SCC lesions was higher than in BCC lesions suggesting 
induction as transformation occurs.  Therefore, that HaCaT cells chronically 
exposed to arsenic are a good model of arsenic-induced SCC not BCC. 
Furthermore, the suppression in expression of both miR-381 and mir-452 is 
suggested to be arsenic-induced BCC phenotype specific. Both miRNAs have 
been reported to be dysregulated in other cancers as discussed in chapter 2. 
MiR-381 is reported to be suppressed in several other cancers including oral 
squamous cell carcinoma, epithelial ovarian cancer, hepatocellular carcinoma, 
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colorectal cancer, gastric cancer, breast cancer, renal cell cancer, colon cancer 
and lung adenocarcinoma (124-133). MiR-452-5p was induced in several 
malignancies (hemangiosarcoma, clear cell renal cell carcinoma and bladder 
cancer), but suppressed in several other cancers and sarcomas (lung 
adenocarcinoma, chondrosarcoma, gliomas, osteosarcoma, non-small cell lung 
cancer, prostate cancer and head and neck adenoid cystic carcinoma vs. head 
and neck squamous cell carcinoma) (134-143). The results indicate that miR-
362, miR-381 and mir-452 are oncogenes in SCC and tumor suppressors in 
BCC. The results also indicate that HaCaT cells chronically exposed to arsenic 




OVERALL DISCUSSION, CONCLUSIONS AND FUTURE DIRECTIONS 
 
This dissertation investigated the differential miRNA expression in arsenic-
induced human skin cancer and the differential small RNA and mRNA expression 
in HaCaT cells chronically exposed to arsenic. Three different techniques, RT-
qPCR arrays, hybridization microarrays, and RNA-seq, were used to generate 
the expression profiles.  
The studies in this dissertation are the first to characterize and identify miRNAs in 
human arsenic-induced skin lesions. Laser capture microdissection (LCM) was 
used to isolate keratinocytes from premalignant and malignant lesions to allow 
purification of total RNA for miRNA profiling without interference from the other 
skin layers. The results provide original information profiling changes in miRNA 
expression associated with arsenic-induced malignant transformation from 
premalignant HK to SCC and BCC. The results show that the expression of some 
miRNAs was phenotype-related, e.g., SCC or BCC, or stage-related, e.g. 
malignancy or metastasis.   
Early stages of arsenite exposure in vitro induced differential small RNA 
(sno, stem-loop and mature miRNAs) and mRNA expression after 3 and 7 weeks 
chronic exposure, with more differentially expressed mRNAs after 7 weeks. The 
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38 mRNAs differentially expressed at both 3 and 7 weeks that are targets 
of differentially expressed miRNAs, are involved in carcinogenesis pathways 
such as the WNT signaling pathway. MDM2 mRNA was among the 38 mRNAs 
identified as miRNA targets. MDM2 mRNA was induced after 3 weeks and 
suppressed after 7 weeks of arsenite exposure whereas HMG1 was increased at 
both time points. Both MDM2 and HMG1 can regulate TP53 expression. 
Moreover, MDM2 and HMG1 are potential targets of miRNAs suppressed by 
arsenite at both of these time points. The induction in MDM2 and HMG1 
expression along with arsenite inhibiting the 4 miRNAs that target them, lead to 
the prediction that TP53 would be suppressed. However, western blot analyses 
showed that the opposite, i.e., TP53 was induced. However, acetylation of TP53 
was suppressed indicating that the induced TP53 was inactive. Moreover, the 
RNA-seq data showed that DNA repair genes that are known targets of TP53 
were not induced suggesting a dysregulated DNA repair response. Therefore, 
the induction of an inactive TP53 along with the disruption of DNA repair 
response by arsenic suggest increased genomic instability and clastogensis that 
arsenic is known to cause contributing to arsenic-induced carcinogenesis.  
In addition, after 7 weeks chronic exposure, low arsenite induced 
differential gene expression indicated dysregulation of cell cycle control, which 
was confirmed by cell cycle analysis and the slow growth of these cells at the 
early times of chronic exposure. The delay could be related to the induction of 
aneuploidy known to be caused by arsenic exposure (359, 360).  
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Arsenite exposed HaCaT cells grew slower at early times and faster at 
later times. The change in growth rate occurred at 19 weeks. Moreover, HaCaT 
cells chronically exposed to arsenic transformed fully at 28 weeks. Therefore, 
studying the small RNA and mRNA expression profiles and pathways at 19 and 
28 weeks provides novel insight into the sequential changes in miRNA 
expression that occur leading to transformation. A high-throughput screening 
tool, RNA-seq, was used to measure these profiles at 7, 19 and 28 weeks. The 
results showed that more small RNAs and mRNAs were differentially expressed 
after 19 weeks chronic arsenic exposure. The pathway analyses of differentially 
expressed mRNAs and target mRNAs showed that several cancer and 
development-related pathways were dysregulated after 19 weeks.  
The miRNA expression profiles obtained by 3 different techniques in the 
skin lesions and the HaCaT cells were compared. Results of these comparisons 
revealed many similarities but some differences. The lack of reproducibility 
miRNA results between hybridization microarray and validation by RT-qPCR was 
notable. Similarly, the lack of reproducibility in miRNA expression profiles 
between both hybridization microarrays and RNA-seq suggests a higher false 
positive rate with hybridization microarrays, similar to that identified by other 
investigators in other cell systems (358). 
Comparing the miRNA expression profiles between HaCaT cells 
chronically exposed to arsenic and arsenic-induced skin lesion showed that the 
expression of 3 miRNAs was phenotype, e.g., SCC or BCC, related and 
transformation stage related. Moreover, comparing the miRNA profiles of HaCaT 
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cells and skin lesions showed that the HaCaT chronic arsenic exposure model is 
a good model for arsenic-induced SCC as suggested by Pi et al. (39). 
This project used several innovative techniques and approaches that 
strengthen the conclusions. The first was the unique sample set we used to 
measure differential miRNA expression in the arsenic-induced skin tumor. 
Formalin fixed paraffin embedded (FFPE) samples of arsenic-induced HK, BCC 
and SCC obtained from subjects living in the villages in high arsenic districts 
(exposed to >50 ppb) in West Bengal, India were analyzed. The results are 
relevant to the U.S. population because the levels of exposure of the subjects are 
similar to those in many rural areas of the U.S.  
In the cell culture studies, four unexposed and exposed independent 
HaCaT cell cultures were maintained providing statistical power to the results 
obtained from the study. Having multiple independent cultures increased 
confidence level of the results, and allowed statistical analyses with biological 
replicates.  
Studying the miRNA and gene expression changes that a 100 nM sodium 
arsenite exposure induces in a longitudinal study is another strength. Chronic 
arsenic exposure has been demonstrated in previous studies to be associated 
with skin cancers and the hyperproliferation of keratinocytes (361, 362). 
However, the different stages prior to malignant transformation and progression 
have not been studied. Epigenetic changes are a proposed mechanism to 
contribute to arsenic-induced carcinogenicity. Thus, the miRNA expression 
profiling at the different time points of arsenic exposure provide longitudinal 
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epigenetic related changes induced by arsenic at different transformation stages 
in HaCaT cells.  
In addition, we used a concentration of sodium arsenite (100 nM) in our 
studies that is identical to the concentration of arsenic in the sera of individuals 
exposed to high levels of arsenic and who developed multiple arsenic-induced 
cancers including skin cancer that was reported as 100 nM (65). Thus, our study 
is of physiological relevance to human exposure.  
In addition, this dissertation discusses the first obtained miRNA 
expression profiles from human keratinocytes chronically exposed to arsenic in a 
longitudinal study. Thus, the analyses on the obtained miRNAs profiles along 
with their target mRNAs open another avenue in skin cancer research to 
consider epigenetic changes as major players in the development and 
progression of arsenic-induced skin cancer.  
The study has several acknowledged weaknesses starting from the 
arsenic-induced tumors. The sample set used was more than seven years old 
and getting more than 100 ng total RNA for NGS was not possible. Therefore, 
measuring the small RNA and mRNA expression profiles in a newer set of 
arsenic-induced skin tumors using NGS is an important future goal.  
The results in this dissertation provide insight on the potential role of 
miRNAs in arsenic-induced carcinogenesis in general and skin cancer in 
particular. The results suggest that some of the miRNAs described could be 
considered as potential biomarkers or therapy targets for arsenic-induced internal 
cancers. In addition, the results obtained from the comparison between miRNA 
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profiles in skin lesions and longitudinal study of HaCaT cells showed that miR-
362 was suppressed. This result suggests that miR-362 may have a tumor 
suppressor role in arsenic-induced SCC. Therefore, investigating the role of miR-
362 suppression in the induction of SCC phenotype is important and identifying 
therapeutics to increase miR-362 in skin may prevent skin lesions.  
Over all, this dissertation embraces the importance of epigenetic changes 
throughout the different stages of arsenic-induced carcinogenesis. It evaluates 
different available techniques used for profiling miRNAs. It also validates the use 
of an arsenic chronic exposure cell line model (HaCaT cells) as an appropriate 
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miRNA microRNA   
mRNA messenger RNA 
snoRNA human small nucleolar RNA  
scaRNA small Cajal body RNA  
Drosha ribonuclease (RNase) III double-stranded RNA-specific 
ribonuclease Drosha  
Dicer helicase with RNase motif  
TRBP HIV-1 TAR RNA binding protein  
RISC RNA-induced silencing complex  
UTRs untranslated regions 
ORF open reading frame 
HK hyperkeratoses  
SCC squamous cell carcinoma  
cSCC cutaneous squamous cell carcinoma 
BD Bowen’s disease 
BCC basal cell carcinoma  
TPA 12-O-tetradecanoyl phorbol-13- acetate 
UV ultraviolet  
HaCaT immortalized human keratinocytes  
NGS Next-Generation Sequencing  
WHO World Health Organization 
IARC International Agency for Research on Cancer 
FFPE formalin (light fixation) and embedded in paraffin  
 
 172 
H&E hematoxylin and eosin 
LCM Laser Capture Microdissection System 
RT-qPCR reverse transcription quantitative polymerase chain reaction  
DALRD3 DALR anticodon binding domain containing 3 gene 
RTL1 retrotransposon Gag like 1 
ANKRD34C-
AS 
ANKRD34C antisense RNA 1 
SEC24B  SEC24 homolog B, COPII coat complex component gene 
C1orf132 chromosome 1 open reading frame 132 
MIR381HG MIR381 host gene  
GABRE gamma-aminobutyric acid type A receptor epsilon subunit gene 
EIF4H eukaryotic translation initiation factor 4H gene 
PANC-1 human pancreatic carcinoma 
ATSDR United States Agency for Toxic Substances and Disease Registry   
stRNAs small temporal RNAs  
RMA Robust Multi-Array 
TCF7L2  Transcription factor 7-like 2 
PTEN Phosphatase and tensin homolog 
MDM2  mouse double minute 2 homolog 
MDM2-FL  Full length MDM2 
TP53  tumor suppressor p53 
EMT epithelial to mesenchymal transition  
HMG1  High mobility group box 1 protein 
SCAI  suppressor of cancer cell invasion 
RNA-seq RNA sequencing 
p_Eq two sample t-test with equal variances  
p_Ueq two sample t-test with unequal variances  
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NGS Next-generation sequencing  
IPA® Ingenuity® Pathway Analysis  
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